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Abstract
In this opinion, the GMO Panel assessed the four-event stack maize Bt11 9 MIR162 9 1507 9 GA21 and
three of its subcombinations, independently of their origin. The GMO Panel previously assessed the four
single events and seven of their combinations and did not identify safety concerns. No new data on the
single events or the seven subcombinations leading to modiﬁcation of the original conclusions were
identiﬁed. Based on the molecular, agronomic, phenotypic and compositional characteristics, the
combination of the single events in the four-event stack maize did not give rise to food/feed safety
issues. Based on the nutritional assessment of the compositional characteristics of maize
Bt11 9 MIR162 9 1507 9 GA21, foods and feeds derived from the genetically modiﬁed (GM) maize are
expected to have the same nutritional impact as those derived from non-GM maize varieties. In the case
of accidental release of viable grains of maize Bt11 9 MIR162 9 1507 9 GA21 into the environment,
this would not raise environmental safety concerns. The GMO Panel concludes that maize
Bt11 9 MIR162 9 1507 9 GA21 is nutritionally equivalent to and as safe as its non-GM comparator in
the context of the scope of this application. For the three subcombinations included in the scope, for
which no experimental data were provided, the GMO Panel assessed the likelihood of interactions among
the single events and concluded that their combinations would not raise safety concerns. These maize
subcombinations are therefore expected to be as safe as the single events, the previously assessed
subcombinations and the four-event stack maize. The post-market environmental monitoring plan and
reporting intervals are in line with the intended uses of maize Bt11 9 MIR162 9 1507 9 GA21 and its
subcombinations. A minority opinion expressed by a GMO Panel member is appended to this opinion.
© 2018 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
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Summary
Following the submission of application EFSA–GMO–DE–2010–86 under Regulation (EC) No 1829/
2003 from Syngenta, the Panel on Genetically Modiﬁed Organisms of the European Food Safety Authority
(referred to hereafter as the GMO Panel) was asked to deliver a scientiﬁc opinion on the safety of
genetically modiﬁed (GM) herbicide-tolerant and insect-resistant maize Bt11 9 MIR162 9 1507 9 GA21
(referred to hereafter as ‘four-event stack maize’) and its subcombinations independently of their origin
(referred to hereafter as ‘subcombinations’). The scope of application EFSA-GMO-DE-2010-86,
which included all subcombinations at the time of submission, was subsequently limited to include
three subcombinations only. The scope of application EFSA-GMO-DE-2010-86 as assessed in
this Scientiﬁc Opinion is for the placing on the market of maize Bt11 9 MIR162 9 1507 9 GA21
and three subcombinations (Bt11 9 MIR162 9 1507, MIR162 9 1507 9 GA21 and MIR162 9 1507),
independently of their origin, for food and feed uses, import and processing.
The term ‘subcombination’ refers to any combination of up to three of the events present in the
four-event stack maize Bt11 9 MIR162 9 1507 9 GA21. In the present GMO Panel Scientiﬁc Opinion,
the safety of subcombinations occurring as segregating progeny in the harvested grains of maize
Bt11 9 MIR162 9 1507 9 GA21 is evaluated in the context of the assessment of the four-event stack
maize. The safety of subcombinations that either have been or could be produced by conventional
crossing through targeted breeding approaches, and which can be bred, produced and marketed
independently of the four-event stack maize, is assessed in a separate section of the Scientiﬁc Opinion.
In delivering its Scientiﬁc Opinion, the GMO Panel considered the data available on the single
events, the four-event stack maize, the previously assessed subcombinations, the scientiﬁc comments
submitted by the Member States and relevant scientiﬁc literature. The four-event stack maize
Bt11 9 MIR162 9 1507 9 GA21 was produced by conventional crossing to combine four single maize
events: Bt11, expressing the Cry1Ab protein for protection against some lepidopteran pests and the
phosphinothricin acetyltransferase (PAT) protein for tolerance to glufosinate-ammonium-containing
herbicides; MIR162, expressing the Vip3Aa20 protein for protection against some lepidopteran pests
and the phosphomannose isomerase (PMI) protein used as a selectable marker; 1507, expressing the
Cry1F protein for protection against some lepidopteran pests and the PAT protein for tolerance to
glufosinate-ammonium-containing herbicides; and GA21, expressing the mutated 5-enolpyruvyl-
shikimate-3-phosphate synthase (mEPSPS) protein for tolerance to glyphosate-containing herbicides.
The GMO Panel evaluated the four-event stack maize and three of its subcombinations with
reference to the scope and appropriate principles described in its guidelines for the risk assessment of
GM plants and derived food and feed, the environmental risk assessment of GM plants and the post-
market environmental monitoring of GM plants. The GMO Panel Guidance Documents establish the
principle that where all single events have been assessed, the risk assessment of stacked events
should focus mainly on issues related to (a) stability of the inserts, (b) expression of the introduced
genes and their products and (c) potential synergistic or antagonistic effects resulting from the
combination of the events.
For application EFSA-GMO-DE-2010-86, the previous assessments of the four single maize events
and seven subcombinations provided a basis to evaluate the four-event stack maize and the three
subcombinations included in the scope of the application. The four single maize events (Bt11, MIR162,
1507 and GA21) and seven subcombinations (Bt11 9 GA21 9 MIR162, Bt11 9 1507 9 GA21,
Bt11 9 GA21, MIR162 9 GA21, Bt11 9 MIR162, Bt11 9 1507 and 1507 9 GA21) were previously
assessed by the GMO Panel and no concerns on their safety were identiﬁed. No safety issue
concerning the four single maize events was identiﬁed by the updated bioinformatic analyses nor
reported by the applicant since the publication of the previous GMO Panel Scientiﬁc Opinions.
Therefore, the GMO Panel considers that its previous conclusions on the safety of the single maize
events remain valid.
For the four-event stack maize, the risk assessment included the molecular characterisation of the
inserted DNA and analysis of protein expression. An evaluation of the comparative analyses of
agronomic/phenotypic and compositional characteristics was undertaken, and the safety of the newly
expressed proteins and the whole food/feed were evaluated with respect to potential toxicity,
allergenicity and nutritional characteristics. An evaluation of environmental impacts and post-market
environmental monitoring plans was also undertaken.
The molecular data establish that the events stacked in maize Bt11 9 MIR162 9 1507 9 GA21
have retained their integrity. Protein expression analyses showed that the levels of the newly
expressed proteins are similar in the four-event stack maize and in the single events except for the
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expected difference for PAT protein levels resulting from the combination of Bt11 and 1507 events,
both producing PAT protein in the four-event stack. No indications of interactions that may affect the
integrity of the events and the levels of the newly expressed proteins in this four-event stack maize
were identiﬁed.
The comparative analysis of forage and grain composition and agronomic/phenotypic characteristics
identiﬁed no differences between maize Bt11 9 MIR162 9 1507 9 GA21 and the non-GM comparator
that required further assessment for food/feed safety or environmental impact, except for a decrease
of b-carotene, b-cryptoxanthin and lutein in GM maize grain.
The combination of maize Bt11, MIR162, 1507 and GA21 and of the newly expressed proteins in
the four-event stack maize did not give rise to issues regarding food and feed safety. Based on the
nutritional assessment of the levels of b-carotene, b-cryptoxanthin and lutein in the GM maize, the
GMO Panel concludes that foods and feeds derived from maize Bt11 9 MIR162 9 1507 9 GA21 are
expected to have the same nutritional impact as those derived from non-GM commercial maize
varieties.
Considering the combined events, the outcome of the comparative analysis and the routes and
levels of exposure, the GMO Panel concludes that this four-event stack maize would not raise safety
concerns in the case of accidental release of viable GM maize grains into the environment.
The GMO Panel concludes that the four-event stack maize is as safe as the non-GM comparator
with respect to potential effects on human and animal health and the environment in the context of
the scope of this application.
Maize Bt11 9 MIR162 9 1507 9 GA21 has 10 possible subcombinations, seven of which have been
previously assessed and are not included in the scope of application EFSA-GMO-DE-2010-86. The three
remaining subcombinations (Bt11 9 MIR162 9 1507, MIR162 9 1507 9 GA21 and MIR162 9 1507)
were not previously assessed and are included in the scope of the application. For these
subcombinations, for which no experimental data were provided, the GMO Panel assessed the
possibility of interactions between the events and concluded that these combinations of maize events
Bt11, MIR162, 1507 and GA21 would not raise safety concerns. The three maize subcombinations are
therefore expected to be as safe as the single events, the previously assessed subcombinations and
the four-event stack maize Bt11 9 MIR162 9 1507 9 GA21.
Given the absence of safety concerns for food and feed derived from maize
Bt11 9 MIR162 9 1507 9 GA21 and its subcombinations, the GMO Panel considers that post-market
monitoring of these products is not necessary. The post-market environmental monitoring plan and
reporting intervals are in line with the intended uses of the four-event stack maize and its
subcombinations.
A minority opinion expressed by a GMO Panel member is presented in Appendix B of this opinion.
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1. Introduction
1.1. Background
On 10 August 2010, the European Food Safety Authority (EFSA) received from the Competent
Authority of Germany application EFSA-GMO-DE-2010-86, for authorisation of GM maize
Bt11 9 MIR162 9 1507 9 GA21 submitted by Syngenta (referred to hereafter as ‘the applicant’)
within the framework of Regulation (EC) No 1829/20031 on GM food and feed for food and feed uses,
import and processing.
After receiving application EFSA-GMO-DE-2010-86 and in accordance with Articles 5(2)(b) and 17(2)
(b) of Regulation (EC) No 1829/2003, EFSA informed Member States and the European Commission,
and made the summary of the application available to the public on the EFSA website.2 EFSA initiated a
formal review of the application to check compliance with the requirements laid down in Articles 5(3)
and 17(3) of Regulation (EC) No 1829/2003. On 26 January 2011, 25 March 2011, 21 December 2011
and 2 April 2012, EFSA received additional information under completeness check (requested on 11
October 2010, 4 March 2011 and 25 January 2012, respectively). On 14 June 2012, EFSA declared the
application valid in accordance with Articles 6(1) and 18(1) of Regulation (EC) No 1829/2003.
EFSA made the valid application available to Member States and the European Commission and
consulted nominated risk assessment bodies of Member States, including national Competent
Authorities within the meaning of Directive 2001/18/EC3 following the requirements of Articles 6(4)
and 18(4) of Regulation (EC) No 1829/2003 to request their scientiﬁc opinion. Member States had
3 months after the date of receipt of the valid application (until 18 September 2012) to make their
opinion known.
The scope deﬁned by the applicant at the time of submission was ‘all food and feed products
containing, consisting or produced from Bt11 9 MIR162 9 1507 9 GA21 maize including products
from inbreds and hybrids obtained by conventional breeding of this stacked maize product. The
application also covers the import and industrial processing of Bt11 9 MIR162 9 1507 9 GA21 maize
for all potential uses as any other maize.’ After clariﬁcations (letters dated 15 March 2012, 6 June
2012, 18 February 2014, 8 December 2015 and 31 March 2016), the applicant notiﬁed EFSA that the
scope of application EFSA-GMO-DE-2010-86 was limited to ‘Bt11 9 MIR162 9 1507 9 GA21 maize
and three subcombinations from Bt11 9 MIR162 9 1507 9 GA21 maize (Bt11 9 MIR162 9 1507,
MIR162 9 1507 9 GA21 and MIR162 9 1507) independently of their origin.’
The genetically modiﬁed organism (GMO) Panel carried out an evaluation of the scientiﬁc risk
assessment of GM maize Bt11 9 MIR162 9 1507 9 GA21 and the three subcombinations listed above.
The GMO Panel requested additional information from the applicant on 31 October 2012 (EURL-GMFF),
7 December 2012, 5 February 2013, 27 September 2013, 4 June 2014, 16 September 2014, 3 October
2014, 10 November 2014, 22 September 2015, 23 December 2015, 4 August 2016, 1 February 2017,
18 May 2017, 20 December 2017, 18 January 2018 and 16 February 2018. The applicant provided the
requested information on 16 November 2012 (EURL-GMFF), 26 April 2013, 16 June 2014, 23 June
2014, 30 September 2014, 21 November 2014, 28 November 2014, 12 March 2015, 30 July 2015, 10
August 2015, 9 September 2015, 24 September 2015, 4 April 2016, 3 November 2016, 12 June 2017,
14 December 2017, 5 March 2018, 5 April 2018 and 30 April 2018. The applicant also provided
spontaneously additional information on 28 July 2014, 21 July 2015, 17 December 2015, 25 November
2016 and 4 October 2017.
In the context of contract OC/EFSA/UNIT/GMO/2013/01, the contractors performed preparatory
work and delivered reports on the methods applied by the applicant in performing bioinformatic
analyses.
In giving its scientiﬁc opinion to the European Commission, the Member States and the applicant,
and in accordance with Articles 6(1) and 18(1) of Regulation (EC) No 1829/2003 (European
Commission, 2003), EFSA has endeavoured to respect a time limit of 6 months from the
acknowledgement of the valid application. As additional information was requested by the GMO Panel,
the time limit of 6 months was extended accordingly, in line with Articles 6(1), 6(2), 18(1) and 18(2)
of Regulation (EC) No 1829/2003.
1 Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modiﬁed
food and feed. Ofﬁcial Journal of the European Communities, L268, 1–23.
2 Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-2010-01087
3 Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the
environment of genetically modiﬁed organisms and repealing Council Directive 90/220/EEC. OJ L 106, 12.3.2001, p. 1–38.
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According to Regulation (EC) No 1829/2003 (European Commission, 2003), this scientiﬁc opinion is
to be seen as the report requested under Articles 6(6) and 18(6) of that Regulation and thus will be
part of the EFSA overall opinion in accordance with Articles 6(5) and 18(5).
1.2. Terms of Reference as provided by the requestor
The GMO Panel was requested to carry out a scientiﬁc risk assessment of
‘Bt11 9 MIR162 9 1507 9 GA21 maize and three subcombinations from Bt11 9 MIR162 9 1507 9 GA21
maize (Bt11 9 MIR162 9 1507, MIR162 9 1507 9 GA21 and MIR162 9 1507) independently of their
origin’, for food and feed uses, import and processing in accordance with Articles 6(6) and 18(6) of
Regulation (EC) No 1829/2003.
Where applicable, any conditions or restrictions which should be imposed on the placing on the
market and/or speciﬁc conditions or restrictions for use and handling, including post-market monitoring
requirements based on the outcome of the risk assessment and, in the case of GMOs or food/feed
containing or consisting of GMOs, conditions for the protection of particular ecosystems/environment
and/or geographical areas should be indicated in accordance with Articles 6(5)(e) and 18(5)(e) of
Regulation (EC) No 1829/2003.
The GMO Panel was not requested to give an opinion on information required under Annex II to
the Cartagena Protocol. Furthermore, the GMO Panel did not consider proposals for labelling and
methods of detection (including sampling and the identiﬁcation of the speciﬁc transformation event in
the food/feed and/or food/feed produced from it), which are matters related to risk management.
2. Data and methodologies
2.1. Data
In delivering its scientiﬁc opinion, the GMO Panel took into account application EFSA-GMO-DE-2010-
86, additional information provided by the applicant, scientiﬁc comments submitted by the Member
States and relevant scientiﬁc publications.
2.2. Methodologies
The GMO Panel carried out a scientiﬁc risk assessment of maize Bt11 9 MIR162 9 1507 9 GA21
and three subcombinations that have not been authorised previously (Table 1), independently of their
origin, for food and feed uses, import and processing in accordance with Articles 6(6) and 18(6) of
Regulation (EC) No 1829/2003. The GMO Panel took into account the appropriate principles described
in its guidelines for the risk assessment of GM plants and derived food and feed (EFSA, 2006, 2007a;
EFSA GMO Panel, 2011a), for the environmental risk assessment (ERA) of GM plants (EFSA GMO
Panel, 2010a) and for the post-market environmental monitoring (PMEM) of GM plants (EFSA GMO
Panel, 2011b).
The comments raised by Member States are addressed in Annex G of EFSA’s overall opinion and
were taken into consideration during the scientiﬁc risk assessment.2
3. Assessment
3.1. Introduction
Application EFSA-GMO-DE-2010-86 covers four events: the four-event stack maize
Bt11 9 MIR162 9 1507 9 GA21 and three subcombinations that have not been authorised previously,
independently of their origin (Table 1). The scope of this application is for food and feed uses, import
and processing, and excludes cultivation within the European Union (EU).
The term ‘subcombination’ refers to combinations of up to three of the events present in the four-
event stack maize.
The safety of subcombinations occurring as segregating progeny in harvested grains of maize
Bt11 9 MIR162 9 1507 9 GA21 is evaluated in the context of the assessment of the four-event stack
maize in Section 3.3 of this GMO Panel Scientiﬁc Opinion.
‘Subcombination’ also covers combinations of up to three of the events Bt11, MIR162, 1507 and
GA21 that either have been or could be produced by conventional crossing through targeted breeding
approaches (EFSA GMO Panel, 2011a). These are maize stacks that can be bred, produced and
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marketed independently of the four-event stack maize. Seven of these subcombinations have already
been assessed by the GMO Panel. The three remaining subcombinations are assessed in Section 3.4 of
this GMO Panel Scientiﬁc Opinion.
The four-event stack maize was produced by conventional crossing to combine four single maize
events: Bt11 (expressing the Cry1Ab and phosphinothricin acetyltransferase (PAT) proteins); MIR162
(expressing the Vip3Aa20 and phosphomannose isomerase (PMI) proteins); 1507 (expressing the
Cry1F and PAT proteins); and GA21 (expressing the mutated 5-enolpyruvyl-shikimate-3-phosphate
synthase (mEPSPS) protein).
Herbicide tolerance traits are achieved by the expression of the PAT and mEPSPS proteins (for
tolerance to glufosinate-ammonium- and glyphosate-containing herbicides, respectively). Insect
resistance traits are achieved by the expression of the Cry1Ab, Cry1F and Vip3Aa20 proteins, which
confer protection against speciﬁc lepidopteran pests, such as Ostrinia nubilalis (European corn borer)
and Sesamia nonagrioides (Mediterranean corn borer).
The four single maize events and seven subcombinations have been previously assessed by the
GMO Panel (Table 2), and no safety concerns were identiﬁed.
Table 1: The four maize events covered by the scope of application EFSA-GMO-DE-2011-86
Degree of stacking Events Unique Identiﬁers
Four-event stack maize Bt11 9 MIR162 9 1507 9 GA21 SYN-BTØ11-1 x SYN-IR162-4 x DAS-Ø15Ø7-1 x
MON-ØØØ21-9
Three-event stack maize Bt11 9 MIR162 9 1507 SYN-BTØ11-1 x SYN-IR162-4 x DAS-Ø15Ø7-1
MIR162 9 1507 9 GA21 SYN-IR162-4 x DAS-Ø15Ø7-1 x MON-ØØØ21-9
Two-event stack maize MIR162 9 1507 SYN-IR162-4 x DAS-Ø15Ø7-1
Table 2: Single maize events and subcombinations of maize Bt11 9 MIR162 9 1507 9 GA21
already assessed by the GMO Panel
Events Application or mandate Reference
Bt11 C/F/96/05.10
EFSA-GMO-RX-Bt11
EFSA-M-2012-0232(a)
EFSA (2005a)
EFSA (2009a)
EFSA GMO Panel (2012a)
MIR162 EFSA-GMO-DE-2010-82 EFSA GMO Panel (2012b)
1507 C/NL/00/10
C/ES/01/0
EFSA-GMO-UK-2004-02
EFSA-GMO-RX-1507
EFSA-M-2012-0231(b)
EFSA-GMO-RX-001
EFSA (2004)
EFSA (2005b)
EFSA (2005c)
EFSA (2009b)
EFSA GMO Panel (2012c)
EFSA GMO Panel (2017a)
GA21 EFSA-GMO-UK-2005-19
EFSA-GMO-RX-GA21
EFSA-GMO-RX-005
EFSA (2007b)
EFSA (2007b)
EFSA GMO Panel (2017b)
Bt11 x GA21 EFSA-GMO-UK-2007-49 EFSA GMO Panel (2009a)
Bt11 x GA21 x MIR162 EFSA-GMO-DE-2009-66 EFSA GMO Panel (2015a)
MIR162 x GA21 EFSA-GMO-DE-2009-66 EFSA GMO Panel (2015a)
Bt11 x MIR162 EFSA-GMO-DE-2009-66
EFSA-M-2016-0248(c)
EFSA GMO Panel (2015a)
EFSA GMO Panel (2017c)
Bt11 x 1507 x GA21 EFSA-GMO-DE-2011-99
EFSA-M-2017-0169(d)
EFSA GMO Panel (2016)
EFSA GMO Panel (2017d)
Bt11 x 1507 EFSA-GMO-DE-2011-99 EFSA GMO Panel (2016)
1507 x GA21 EFSA-GMO-DE-2011-99 EFSA GMO Panel (2016)
(a): Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-2012-00713
(b): Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-2012-00712
(c): Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q- 2016-00730
(d): Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-2017-00669
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EFSA guidance establishes the principle that ‘For GM plants containing a combination of
transformation events (stacked events), the primary concern for risk assessment is to establish that
the combination of events is stable and that no interactions between the stacked events, that may
raise safety concerns compared to the single events, occur. The risk assessment of GM plants
containing stacked events focuses on issues related to: (a) stability of the inserts, (b) expression of the
introduced genes and their products and (c) potential synergistic or antagonistic effects resulting from
the combination of the events’ (EFSA, 2007a; EFSA GMO Panel, 2011a).
3.2. Updated information on the events
Since the publication of the scientiﬁc opinions of the GMO Panel on the single maize events (see
Table 2), no safety issue pertaining to the four single events has been reported by the applicant.
For maize event GA21, updated nucleotide sequence information was received.4 The new sequence
information revealed a nucleotide change in the actin promoter of copy 6, a three-base pair deletion
contiguous to one nucleotide substitution within the 3’ insert ﬂanking region, and a difference in the
number of complete mepsps cassettes present within the insert, with respect to the sequence
submitted in the original application (EFSA, 2007b). Further analyses demonstrated that these
differences were already present in the original material used for the risk assessment of maize GA21.
The GMO Panel has performed the risk assessment of the new sequencing information for maize event
GA21 in the frame of a request received from the European Commission5 and has concluded that the
original risk assessments of maize event GA21 as a single and as a part of stacked events remain valid
(EFSA GMO Panel, 2015b).
In addition, the applicant clariﬁed that the 1507 maize sequence reported for the four-event stack
maize contained one nucleotide change in the insert sequence compared to the corrected original 1507
maize sequence (EFSA GMO Panel, 2017a). Analysis of the new sequencing data and bioinformatics
analyses performed on the new sequence did not identify any need for further safety assessment.6
Bioinformatics analyses on the junction regions for maize events Bt11, MIR162, 1507 and GA21, using
the most up-to-date nucleotide sequences and methodology speciﬁed in EFSA guidance (EFSA GMO
Panel, 2011a), conﬁrmed that no known endogenous genes were disrupted by any of the inserts.7,8
Updated bioinformatics analyses of the amino acid sequence of the newly expressed Cry1Ab, Cry1F,
Vip3Aa20, PAT, mEPSPS and PMI proteins revealed no signiﬁcant similarities to toxins and
allergens.7,8,9 In addition, updated bioinformatics analyses of the newly created open-reading frames
(ORFs) within the inserts and at their junctions indicated that the expression of an ORF showing
signiﬁcant similarities to toxins or allergens is highly unlikely.7,8,10
Based on the above information, the GMO Panel considers that its previous conclusions on the
safety of the single maize events remain valid.
3.3. Risk assessment of the four-event stack maize
Bt11 3 MIR162 3 1507 3 GA21
3.3.1. Molecular characterisation
Possible interactions that would affect the integrity of the events, newly expressed proteins levels
or the biological function conferred by the individual inserts are considered.
3.3.1.1. Genetic elements and biological functions of the inserts
Maize events Bt11, MIR162, 1507 and GA21 were combined by conventional crossing to produce
the four-event stack maize Bt11 9 MIR162 9 1507 9 GA21. The structures of the inserts introduced
into the four-event stack maize are described in detail in the respective EFSA scientiﬁc opinions
(Table 2) and no new genetic modiﬁcations were involved. Genetic elements in the expression
cassettes of the single events are summarised in Table 3.
4 Additional information: 21/7/2015 and 24/9/2015.
5 Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-2015-00475
6 Additional information: 24/9/2015, 12/6/2017 and 5/4/2018.
7 Additional information: 16/6/2014, 28/7/2014 (spontaneous submission) and 30/9/2014.
8 Additional information: 12/6/2017 and 5/4/2018.
9 Additional information: 30/7/2015.
10 Additional information: 30/7/2015, 17/12/2015 (spontaneous submission) and 4/4/2016.
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Intended effects of the inserts in maize Bt11 9 MIR162 9 1507 9 GA21 are summarised in
Table 4.
Based on the known biological function of the newly expressed proteins (Table 4), the only
foreseen interactions at the biological level are between the two Cry proteins and between the
Vip3Aa20 and the Cry proteins.
Table 3: Genetic elements in the expression cassettes of the events stacked in maize
Bt11 9 MIR162 9 1507 9 GA21
Event Promoter 5’ UTR Transit peptide Coding region Terminator
Bt11 35S
(CaMV)*
IVS6
(Zea mays)
No cry1Ab
(Bacillus thuringiensis)
nos
(Agrobacterium
tumefaciens)
35S
(CaMV)
IVS2
(Zea mays)
No pat
(Streptomyces
viridochromogenes)
nos
(Agrobacterium
tumefaciens)
MIR162 ZmUbiInt
(Zea mays)
– No vip3Aa20
(Bacillus thuringiensis)
35S
(CaMV)
ZmUbiInt
(Zea mays)
– No pmi
(Escherichia coli)
nos
(Agrobacterium
tumefaciens)
1507(a) ubiZM1
(Zea mays)
– No cry1F
(Bacillus thuringiensis)
ORF25PolyA
(Agrobacterium
tumefaciens)
35S
(CaMV)
– No pat
(Streptomyces
viridochromogenes)
35S
(CaMV)
GA21 actin 1
(Oryza sativa)
actin 1
(Oryza sativa)
OTP (Helianthus
annuus)
mepsps
(Zea mays)
nos
(Agrobacterium
tumefaciens)
UTR: untranslated region; CaMV: cauliﬂower mosaic virus.
–: when no element was speciﬁcally introduced to optimise expression.
*: Source of genetic material.
(a): Maize 1507 contains additional partial fragments of the cry1F and pat genes at a single locus in the nuclear genome.
Table 4: Characteristics and intended effects of the events stacked in maize Bt11 9 MIR162 9
1507 9 GA21
Event Protein
Donor organism and biological
function
Intended effects in GM plant
Bt11 Cry1Ab Donor organism: Bacillus thuringiensis var.
kurstaki HD-1. B. thuringiensis is an insect
pathogen; its insecticidal activity is
attributed to the expression of crystal
protein (cry) genes (Schnepf et al., 1998)
Event Bt11 expresses a truncated version of
the Cry1Ab protein. Cry1Ab is a protein
toxic to certain lepidopteran larvae feeding
on maize.
PAT Donor organism: Streptomyces
viridochromogenes T€u494
Phosphinothricin-acetyl-transferase (PAT)
enzyme acetylates L-glufosinate-ammonium
and thereby confers tolerance to
phosphinotricin (Wohlleben et al., 1988)
Expression of PAT in maize Bt11 confers
tolerance to glufosinate-ammonium-based
herbicides.
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3.3.1.2. Integrity of the events in the four-event stack11
The genetic stability of the inserted DNA over multiple generations in the single maize events Bt11,
MIR162, 1507 and GA21 was demonstrated previously (see Table 2). Integrity of these events in maize
Bt11 9 MIR162 9 1507 9 GA21 was demonstrated by Southern analyses.12
3.3.1.3. Information on the expression of the inserts13
Cry1Ab, PAT, Vip3Aa20, PMI, Cry1F and mEPSPS protein levels were analysed by enzyme-linked
immunosorbent assay (ELISA) in material harvested from ﬁeld trials at one single location in the USA14
during the 2008 growing season. Samples analysed included leaves (V10 and R1 stages), root (R1
stage), pollen (R1 stage), whole plant (R1 stage) and grain (R6 stage) (see Appendix A). Grains and
forage are the two main raw commodities used for food and feed purposes. The GMO Panel requested
protein expression data from forage, but the applicant did not provide this information. In the absence
of these data, the data on the highest levels of newly expressed proteins in leaves (V10 or R1 stages)
were used to estimate the levels in forage. The mean values of the protein levels in grains and leaves
of maize Bt11 9 MIR162 9 1507 9 GA21 are summarised in Table 5.
Event Protein
Donor organism and biological
function
Intended effects in GM plant
MIR162 Vip3Aa20 Donor organism: B. thuringiensis strain
AB88 (Estruch et al., 1996). In addition to
Cry proteins, B. thuringiensis also produces
insecticidal proteins during its vegetative
growth stage. These are referred to as
vegetative insecticidal proteins (Fang et al.,
2007)
Event MIR162 expresses a modiﬁed version
of the B. thuringiensis vip3Aa1 gene and
encodes Vip3Aa20, a protein toxic to certain
lepidopteran larvae feeding on maize
PMI Donor organism: E. coli. PMI
(phosphomannose isomerase) catalyses the
isomerisation of mannose-6-phosphate to
fructose-6-phosphate and plays a role in the
metabolism of mannose (Markovitz et al.,
1967)
PMI is used as a selectable marker in maize
MIR162. Mannose normally inhibits root
growth, respiration and germination.
Transformed cells expressing PMI are able
to utilise mannose as a carbon source
(Negrotto et al., 2000)
1507 Cry1F Donor organism: Bacillus thuringiensis
subsp. aizawai. B. thuringiensis is an insect
pathogen; its insecticidal activity is
attributed to the expression of crystal
protein (cry) genes (Schnepf et al., 1998).
Event 1507 expresses a truncated version of
the Cry1F protein. Cry1F is a protein toxic
to certain lepidopteran larvae feeding on
maize.
PAT Donor organism: Streptomyces
viridochromogenes strain T€u494
Phosphinothricin-acetyl-transferase (PAT)
enzyme confers resistance to
phosphinotricin (Thompson et al., 1987;
Wohlleben et al., 1988)
PAT acetylates L-glufosinate-ammonium and
thereby confers tolerance to glufosinate-
ammonium-based herbicides (Droge-Laser
et al., 1994)
GA21 mEPSPS Donor organism: Zea mays.
5-enolpyruvyl-shikimate-3-phosphate
synthase (EPSPS) is an enzyme involved in
the shikimic acid pathway for aromatic
amino acid biosynthesis in plants and
microorganisms (Herrmann, 1995)
The amino acid sequence of the maize
EPSPS enzyme was modiﬁed to render the
maize tolerant to glyphosate. Expression of
mEPSPS confers tolerance to glyphosate-
based herbicides (Lebrun et al., 2003)
11 Dossier: Part I – Section D5.
12 Dossier: Part I – Section D5 and Appendix 2.
13 Dossier: Part I – Section D3.
14 Dossier: Part I – Appendix 9.0 and 9.1.
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In order to assess the changes in protein expression levels which may result from potential
interactions between the events, protein levels were determined for the four-event stack and the
corresponding single events in different parts of the plant. The levels of all the proteins in the four-
event stack and the corresponding single events were similar in all tissues except for PAT and Cry1Ab
in leaves (V10 and R1). For PAT, the difference was expected, resulting from the combination of the
Bt11 and 1507 single events, both producing PAT in the four-event stack. As regards Cry1Ab, the
mean Cry1Ab levels in leaves in the four-event stack were higher than in the corresponding single
event (x4 for V10; x2.7 for R1). Taking into account that Cry1Ab levels in the four-event stack are
similar to those of the corresponding single event in all remaining tissues, the GMO Panel does not
consider the differences in the mean levels of Cry1Ab protein as signiﬁcant and concludes that these
data do not indicate an interaction between the events that may result in signiﬁcant changes in the
levels of newly expressed proteins.
3.3.1.4. Conclusion
The molecular data establish that the events stacked in maize Bt11 9 MIR162 9 1507 9 GA21
have retained their integrity. Protein expression analyses showed that the levels of the newly
expressed proteins are similar in the four-event stack and in the single events. PAT showed in general
the expected higher levels in the stack resulting from the combination of the Bt11 and 1507 single
events. Therefore, there is no indication of an interaction that may affect the integrity of the events
and the levels of the newly expressed proteins in this stack.
Based on the known biological function of the newly expressed proteins (Table 4), the only
foreseen interactions at the biological level are between the two Cry proteins and between the
Vip3Aa20 and the Cry proteins in susceptible insects, which are dealt with in Section 3.3.3.
3.3.2. Comparative analysis
3.3.2.1. Choice of comparator and production of material for the comparative analysis15
Three ﬁeld trial studies for comparative analysis were assessed: one for agronomic and phenotypic
characterisation, one for compositional analysis and an additional study for carotenoid composition.
Maize Bt11 9 MIR162 9 1507 9 GA21 was obtained by conventional crossing of the four single
events. Maize events Bt11, MIR162 and GA21 were introduced in the inbred maize line NP222, while
event 1507 was introduced in inbred maize line 5XH751. As documented by the pedigree, the four
single events were combined in a hybrid maize with genetic background (F1) 5XH751/NP2222. The
same two inbred maize lines (5XH751 and NP2222) were crossed to produce the non-GM hybrid maize
Table 5: Mean values and corresponding standard deviations and ranges of protein levels (lg/g dry
weight) in grain (n = 10) and leaves (n = 10) from maize Bt11 9 MIR162 9 1507 9 GA21
Protein Grain (R6) Leaves (V10/R1)
Cry1Ab 1.07(a)  0.11(b)
[0.91–1.24](c)
16.49  6.17
[2.58–41.93]
PAT –
[< LOD to < LOQ]
4.95  0.54
[4.34–5.91]
Vip3Aa20 28.48  1.37
[26.52–31.52]
74.17  7.02
[50.50–110.12]
PMI 1.24  0.07
[1.01–1.34]
4.79  0.69
[4.1–5.71]
Cry1F 3.56  0.19
[3.08–4.49]
13.32  0.91
[11.06–15.11]
mEPSPS 5.15  0.86
[3.52–7.09]
31.11  4.01
[19.41–55.38]
LOD: values below limit of detection; LOQ: values below limit of quantiﬁcation.
–: not applicable.
(a): mean.
(b): standard deviation.
(c): range.
15 Dossier: Part I – Section D7.1.
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used as comparator. On the basis of the provided pedigree, the GMO Panel considers that hybrid maize
5XH751/NP2222 is a suitable non-GM comparator.
For the analysis of agronomic and phenotypic characteristics, the four-event stack maize and its
non-GM comparator maize 5XH751/NP2222 were grown in 13 locations in the USA in 2008,16
representing the range of environmental conditions under which the four-event stack maize would
typically be grown. At each location, the two test materials were grown in plots within replicated
blocks (four per location) according to a randomised complete block design. Maintenance pesticide
treatment was applied to both maize materials according to local requirements. No treatments of the
four-event stack maize with the intended herbicides were included in the study.17 This experimental
design allows a direct comparison between the four-event stack maize and its non-GM comparator in
the presence of maintenance herbicides only.
For the compositional analysis of forage and grains, a set of ﬁeld trials was performed in six
locations in the USA in 2008.18 At each location, maize Bt11 9 MIR162 9 1507 9 GA21 and its non-
GM comparator maize 5XH751/NP2222 were grown in replicated blocks (three per location) according
to a randomised complete block design. Plant protection products (PPP) were applied to both materials
according to local requirements. The plots with the four-event stack maize were treated with the
intended herbicides (glyphosate and glufosinate-ammonium) on top of PPP.19 This experimental design
allows a direct comparison between the four-event stack maize and its non-GM comparator in the
presence of intended herbicides only. Additionally, in a separate ﬁeld trial study, 20 eight non-GM
commercially available maize lines were grown at eight sites in the USA in 200921 (in a randomised
complete block design with four replicates), in order to establish the range of natural variation for
maize compositional parameters.
During the risk assessment, the applicant provided additional data on carotenoid composition derived
from a ﬁeld trial study carried out in the USA in 2016.22 The study was performed according to the
recommendations of EFSA GMO Panel (2011a). At each of eight ﬁeld trial locations,23 the following
materials were grown in a randomised complete block design with four replicates: maize
Bt11 9 MIR162 9 1507 9 GA21, the non-GM comparator maize 5XH751/NP2222 and three non-GM
commercial reference varieties, all treated (sprayed) with PPP according to local requirements; and maize
Bt11 9 MIR162 9 1507 9 GA21 treated with the intended herbicides (glyphosate and glufosinate-
ammonium) in addition to PPP. A total of six non-GM reference varieties were tested in the study.24
3.3.2.2. Agronomic and phenotypic analysis25,26
Twenty-three parameters related to crop physiology, morphology, development, yield and biotic
stress were measured.27 Data collected for 10 of the 23 parameters28 were subjected to an analysis of
variance (ANOVA) across locations, in order to test for differences between the four-event stack maize
and the non-GM comparator.29 The other parameters were not analysed with formal statistical tests
because they did not fulﬁl the assumptions of ANOVA.30
16 Brookings, SD, Minnesota Lake, MN, Nothrﬁeld, MN, Janesville, WI, New Haven, IN, Beaver Crossing, NE, El Paso, IL,
Bloomington, IL, Shirley, IL, St. Joseph, IL, Mackinaw, IL, La Salle, IL, Marshall, MO.
17 Additional information: 26/4/2016.
18 Stanton, MN, Janesville, WI, New Haven, IN, Beaver Crossing, NE, Bloomington, IL, Marshal, MO.
19 Application dates of intended herbicides were provided for all sites except Janesville, WI. Dossier: Part I – Appendix 15.0.
20 Additional information: 12/3/2015.
21 York, NB, Swanton, OH, Deerﬁeld, MI, Richland, IO, Seymour, IL, York, NB, Kimballton, IO, Elk Horn, IO.
22 Additional information: 4/10/2017.
23 Atlantic, IA, Germansville, PA, Stewardson, IL, York, NE, Richland, IA, Geneva, MN, Wyoming, IL and Carlyle, IL.
24 The six varieties were SY SINCERO, SY GENEROSO, NK PAKO, NK LUCIUS, CISKO and SY PROVIAL.
25 Dossier: Part I – Section D7.4.
26 Dossier: Part I – Section D7.1, Appendix 15.0, 15.2 and 15.3; additional information: 26/4/2013.
27 Parameters analysed for agronomic and phenotypic characteristics: grain moisture, grain yield, % stalk lodging, % barren
plants, ear height, % plants with dropped ears, % snapped plants, emerged plants, early emergence vigour, early growth
vigour, plant population at harvest, heat units to 50% silking, heat units to 50% pollen shed, plant height, test weight, grey
leaf spot, late season intactness, leaf colour rating, northern corn leaf blight, southern corn leaf blight, push test, % early root
lodging and % late root lodging.
28 Emerged plants, early emergence vigour, ear height, grain moisture, plant population at harvest, heat units to 50% silking,
heat units to 50% pollen shed, plant height, test weight and grain yield.
29 The model used for the ANOVA included the effect of genotype, location, block-within-location and genotype-by-location.
30 % stalk lodging, % barren plants, % plants with dropped ears, % snapped plants, early growth vigour, grey leaf spot, late
season intactness, leaf colour rating, northern corn leaf blight, southern corn leaf blight, push test, % early root lodging, %
late root lodging. The GMO Panel also noted that some endpoints were recorded at a limited number of sites only: early
emergence vigour at three sites and % early root lodging at two sites (additional information: 26/4/2013).
Assessment of maize Bt11 x MIR162 x 1507 x GA21 and subcombinations
www.efsa.europa.eu/efsajournal 13 EFSA Journal 2018;16(7):5309
Statistically signiﬁcant differences between the four-event stack maize and its non-GM comparator
were observed for the endpoints ‘% emerged plants’, ‘heat units to 50% silking’ and ‘heat units to
50% pollen shed’.31
These signiﬁcant differences are not considered relevant for human and animal health, but are
further assessed for their potential environmental impact in Section 3.3.4.
3.3.2.3. Compositional analysis32
Grain and forage harvested from the ﬁeld trials in the USA in 2008 were analysed for 65
constituents (nine in forage and 56 in grains) including the key constituents recommended by OECD
(OECD, 2002). Six grain constituents were not statistically analysed.33 The data for the remaining
constituents (nine in forage34 and 50 in grains35 ) were analysed with ANOVA, in order to test for
differences between maize Bt11 9 MIR162 9 1507 9 GA21 and the non-GM comparator.29 In case a
signiﬁcant difference was identiﬁed, the level of the parameter in the four-event stack maize was
compared to the values reported in the literature and to the levels occurring in the eight commercial
non-GM maize varieties grown in the USA in 2009.20
No signiﬁcant differences in the composition of forage were observed between maize
Bt11 9 MIR162 9 1507 9 GA21 and its non-GM comparator. Signiﬁcant differences in grain
composition are shown in Table 6. The levels of most amino acids were lower in maize
Bt11 9 MIR162 9 1507 9 GA21 than in the non-GM comparator; this effect was likely linked to the
difference observed in protein content. Except for b-carotene, the levels of all the signiﬁcantly different
endpoints fell within the range of compositional values obtained from the 2009 ﬁeld trials and from the
literature (OECD, 2002). The mean levels of b-carotene in the GM maize (0.031 mg/100 g dry weight
(DW)) were about 50% lower than those in the non-GM comparator (0.061 mg/100 g DW); the levels
also fell outside the range obtained from the 2009 ﬁeld trials and were close to the lower limit
described in the literature (OECD, 2002; Owens et al., 2014).
Table 6: Composition of maize grains: mean values (estimated from the 2008 ﬁeld trials in the
USA) of endpoints for which signiﬁcant differences were found between the GM maize and
the non-GM comparator
Endpoint
Maize
Bt11 3 MIR162 3 1507 3 GA21
Non-GM comparator
5XH571/NP2222
Fat (% DW) 4.33 4.53
Crude protein (% DW) 8.88 9.40
Carbohydrates (% DW) 85.40 84.69
Iron (mg/kg DW) 19.3 20.0
Manganese (mg/kg DW) 5.65 6.41
Phosphorus (mg/kg DW) 2972 2818
Potassium (mg/kg DW) 4217 3882
Zinc (mg/kg DW) 17.7 20.2
b-carotene (mg/100 g DW) 0.031 0.061
Niacin (mg/100 g DW) 2.96 2.69
Threonine (mg/g DW) 3.09 3.27
31 Mean values for ‘% emerged plants’: 64 (GM maize) and 63 (non-GM comparator). Mean values for ‘heat units to 50%
silking’: 1327 (GM maize) and 1315 (non-GM comparator). Mean values for ‘heat units to 50% pollen shed’: 1332 (GM maize)
and 1320 (non-GM comparator).
32 Dossier: Part I – Section D7.4, Appendix 13.0, 13.1, 13.2 and 13.3; additional information: 23/6/2014, 12/3/2015, 4/10/2017
and 5/4/2018.
33 Levels of selenium, sodium, vitamin E, furfural and rafﬁnose were not analysed because most of the data were below the limit
of quantiﬁcation. Moisture levels were not analysed as the grains were dried before the analytical measurements.
34 Proximates (moisture, protein, fat, ash and carbohydrates), ﬁbre fractions (acid detergent ﬁbre (ADF) and neutral detergent
ﬁbre (NDF)) and minerals (calcium and phosphorus).
35 Proximates (ash, carbohydrates, crude fat and protein), ﬁbre fractions (acid detergent ﬁbre, neutral detergent ﬁbre and total
dietary ﬁbre (TDF)), starch, minerals (calcium, copper, iron, magnesium, manganese, phosphorus, potassium and zinc),
vitamins (b-carotene, thiamine, riboﬂavin, niacin, pyridoxine and folic acid), fatty acids (palmitic acid (16:0), stearic acid
(18:0), oleic acid (18:1), linoleic acid (18:2) and linolenic acid (18:3)), amino acids (alanine, arginine, aspartic acid, cysteine,
glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, proline, phenylalanine, proline, serine, tryptophan,
tyrosine and valine) and other compounds (ferulic acid, inositol, p-coumaric acid, phytic acid and trypsin inhibitor).
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The decrease in b-carotene observed in maize Bt11 9 MIR162 9 1507 9 GA21 might indicate
changes in the carotenoid pathway: in the synthesis of all-trans-lycopene (the precursor of both a- and
b-carotene), in the synthesis of lutein (downstream of a-carotene) or in the synthesis of b-
cryptoxanthin and zeaxanthin (downstream of b-carotene) (Yuan et al., 2015). In order to characterise
both branches of the pathway, the GMO Panel requested analytical data on other carotenoids in the
pathway in maize Bt11 9 MIR162 9 1507 9 GA21.
The applicant provided data on six carotenoids (a-carotene, b-carotene, b-cryptoxanthin, lutein,
lycopene and zeaxanthin) derived from a ﬁeld trial study carried out in the USA in 2016.22 Materials
included were maize Bt11 9 MIR162 9 1507 9 GA21 (treated and not treated with the intended
herbicides), the non-GM comparator maize 5XH751/NP2222 and six non-GM commercial varieties.
The levels for a-carotene and lycopene had more than 50% of the measurements below the limit of
quantiﬁcation and were consequently excluded from the statistical analysis. The data on the levels of
b-carotene, b-cryptoxanthin, lutein and zeaxanthin were analysed using the tests of difference and
equivalence as speciﬁed by EFSA GMO Panel (2010b, 2011a).36
The test of difference identiﬁed signiﬁcant differences between maize Bt11 9 MIR162 9 1507 9 GA21
(both treated and not treated) and the non-GM comparator for all four carotenoids in grains. Zeaxanthin
fell in equivalence category I, while the remaining three carotenoids fell into equivalence category III
or IV. Mean estimates for the endpoints showing signiﬁcant differences between maize
Bt11 9 MIR162 9 1507 9 GA21 and the non-GM comparator and falling under category III/IV are given
in Table 7.
Endpoint
Maize
Bt11 3 MIR162 3 1507 3 GA21
Non-GM comparator
5XH571/NP2222
Serine (mg/g DW) 4.19 4.48
Glutamic acid (mg/g DW) 16.2 17.4
Proline (mg/g DW) 7.69 8.29
Glycine (mg/g DW) 3.53 3.71
Alanine (mg/g DW) 6.66 7.07
Cysteine (mg/g DW) 2.07 2.21
Methionine (mg/g DW) 1.81 1.98
Histidine (mg/g DW) 2.51 2.66
Stearic acid (% FA) 2.44 2.39
Oleic acid (% FA) 29.69 30.07
Linoleic acid (% FA) 51.83 51.63
p-Coumaric acid (mg/kg DW) 154 170
Phytic acid (% DW) 0.94 0.86
DW: dry weight; % FA: percentage of total fatty acids.
36 This includes, for each of the two treatments of the GM maize, the application of a difference test (between the GM maize
and the non-GM comparator) and an equivalence test (between the GM maize and the set of non-GM commercial reference
varieties). The results of the equivalence test are categorised into four possible outcomes: category I (indicating full
equivalence to the non-GM reference varieties); category II (equivalence is more likely than non-equivalence); category III
(non-equivalence is more likely than equivalence) and category IV (indicating non-equivalence).
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3.3.2.4. Conclusion
The GMO Panel concluded that the differences in agronomic and phenotypic characteristics
identiﬁed between maize Bt11 9 MIR162 9 1507 9 GA21 and its non-GM comparator do not require
further assessment, except for ‘% emerged plants’, ‘heat units to 50% silking’ and ‘heat units to 50%
pollen shed’. These differences are further assessed for their potential environmental impact in
Section 3.3.4.
The GMO Panel assessed all the compositional differences between the GM maize and the non-GM
comparator, taking into account the potential impact on plant metabolism, the variability reported in
the literature and, for carotenoid composition, the natural variability observed for the set of non-GM
reference varieties. The GMO Panel concluded that no differences require further assessment for
food/feed safety except those observed for b-carotene, b-cryptoxanthin and lutein (Section 3.3.3).
3.3.3. Food and feed safety assessment
3.3.3.1. Effect of processing37
Maize Bt11 9 MIR162 9 1507 9 GA21 will undergo existing production processes used for
conventional maize. No novel production process is envisaged. Therefore, processing of maize
Bt11 9 MIR162 9 1507 9 GA21 into food and feed products is not expected to result in products
being different from those derived from non-GM varieties.
3.3.3.2. Toxicology
Toxicological assessment of newly expressed proteins
Six proteins are newly expressed in the four-event stack maize (Section 3.3.1.3). The GMO
Panel previously assessed these proteins individually in the context of the single events, and no safety
concern was identiﬁed.
The three enzymatic proteins (PAT, PMI and mEPSPS) act on unrelated substrates and are not
expected to interact. The three insecticidal proteins (Cry1Ab, Vip3Aa20 and Cry1F) act through cellular
receptors found in target insect species. It is reported that the gastrointestinal tract of mammals,
including humans, lacks receptors with speciﬁc high afﬁnity to Cry proteins (Hammond et al., 2013;
Koch et al., 2015).
On the basis of the known biological function of the newly expressed proteins (Table 4), there is
currently no expectation for possible interactions relevant to the food and feed safety assessment of
the four-event stack maize Bt11 9 MIR162 9 1507 9 GA21.
The GMO Panel concludes that based on current knowledge, there are no safety concerns to
human and animal health related to the newly expressed proteins Cry1Ab, PAT, Vip3Aa20, PMI, Cry1F
and mEPSPS in the four-event stack maize Bt11 9 MIR162 9 1507 9 GA21.
Table 7: Carotenoids from maize grains: means (for the GM maize, the non-GM comparator and the
set of non-GM reference varieties) and equivalence limits (from the non-GM reference
varieties) estimated from the 2016 ﬁeld trials in the USA
Endpoint
(b)(mg/100 g
DW)
Maize
Bt11 3 MIR162 3 1507 3 GA21 Non-GM
comparator
Non-GM reference varieties
Not treated(a) Treated(a) Mean Equivalence limits
b-Carotene 0.0384* 0.0352* 0.0716 0.155 (0.056, 0.426)
b-Cryptoxanthin 0.0293* 0.0292* 0.0463 0.0928 (0.0347, 0.246)
Lutein 0.512* 0.500* 0.750 1.39 (0.668, 2.91)
DW: dry weight.
For the GM maize, signiﬁcantly different entries are marked with an asterisk, while the outcomes of the test of equivalence are
differentiated by greyscale backgrounds: light grey (equivalence category III) and dark grey (equivalence category IV).
(a): Treated: treated with glyphosate- and glufosinate-ammonium; Not treated: treated only with conventional herbicides (see
Section 3.3.2.1).
(b): The GMO Panel noted that no information was provided by the applicant on the recovery of the analytical method for the
carotenoids analysed. This does not affect the outcome of the comparative risk assessment in application EFSA-GMO-DE-
2010-86.
37 Dossier: Part I – Section D7.6.
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Toxicological assessment of components other than newly expressed proteins
The compositional differences observed in the four-event stack maize with respect to its non-GM
comparator did not require toxicological assessment (see Section 3.3.2.3).
3.3.3.3. Animal studies with the food/feed derived from GM plants
No animal studies with food/feed derived from maize Bt11 9 MIR162 9 1507 9 GA21 were
provided by the applicant. No compositional modiﬁcations relevant for safety or nutrition are expected
in food and feed derived from the four-event stack maize (Sections 3.3.2 and 3.3.3.5), and there was
no indication of interactions relevant for food/feed safety (Sections 3.3.1 and 3.3.2). Therefore, animal
feeding studies are not considered necessary (EFSA, 2006; EFSA GMO Panel, 2011a).
3.3.3.4. Allergenicity
For the allergenicity assessment, a weight-of-evidence approach was followed, taking into account
all of the information obtained on the newly expressed proteins, since no single piece of information or
experimental method yields sufﬁcient evidence to predict allergenicity (EFSA, 2006; Codex
Alimentarius, 2009). In addition, when known functional aspects of the newly expressed protein or
structural similarity to known adjuvants may indicate an adjuvant activity, the possible role of these
proteins as adjuvants is considered. When newly expressed proteins with a potential adjuvant activity
are expressed together, possible interactions increasing adjuvanticity and impacting the allergenicity of
the GM crop are assessed.
Assessment of allergenicity of the newly expressed proteins38
The GMO Panel previously evaluated the safety of the Cry1Ab, Cry1F, Vip3Aa20, PAT, mEPSPS and
PMI proteins individually, and no concerns on allergenicity were identiﬁed in the context of the
applications assessed (see EFSA scientiﬁc opinions listed in Table 2). No new information on
allergenicity of these proteins that might change the previous conclusions of the GMO Panel has
become available. Based on current knowledge, and as none of the newly expressed proteins showed
allergenicity, no reasons for concerns regarding the simultaneous presence of these newly expressed
proteins in this four-event stack maize affecting allergenicity were identiﬁed.
For adjuvanticity, proteins derived from Bacillus thuringiensis (Bt proteins) have been suggested to
possess adjuvant activity, based on animal studies on Cry1Ac when applied at relatively high doses
(e.g. Vazquez et al., 1999). The Panel previously evaluated the safety of the Cry1Ab, Cry1F and
Vip3Aa20 proteins and no concerns on adjuvanticity in the context of the applications assessed were
identiﬁed (see EFSA scientiﬁc opinions listed in Table 2). The levels of Bt proteins in the four-event
stack maize are similar to those in the respective single maize events (see Table 5). From the limited
experimental evidence available, the GMO Panel did not ﬁnd indications that the presence of the Bt
proteins at the levels expressed in the four-event stack maize might act as adjuvants with the potential
to enhance a speciﬁc immunoglobulin E (IgE) response and to favour the development of an allergic
reaction.
Assessment of allergenicity of GM plant products39
The GMO Panel regularly reviews the available publications on food allergy to maize. However, to
date, maize has not been considered to be a common allergenic food40 (OECD, 2002). Therefore, the
GMO Panel did not request experimental data to analyse the allergen repertoire of GM maize.
In the context of this application and considering the data from the molecular characterisation, the
compositional analysis and the assessment of the newly expressed proteins (see Sections 3.3.1,
3.3.2.3 and 3.3.3.2), the GMO Panel identiﬁed no indications of a potentially increased allergenicity of
food and feed derived from the four-event stack maize with respect to that derived from its non-GM
comparator.
38 Dossier: Part I – Section D7.9; additional information: 30/7/2015; 17/12/2015 (spontaneous submission), 4/4/2016 and 26/4/
2013.
39 Dossier: Part I – Section D7.9.
40 Directive 2007/68/EC of the European Parliament and of the Council of 27 November 2007 amending Annex IIIa to Directive
2000/13/EC of the European Parliament and of the Council as regards certain food ingredients. OJ L 310, 27.11.2007, p. 11–14.
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3.3.3.5. Nutritional assessment of GM food/feed41
The intended traits of maize Bt11 9 MIR162 9 1507 9 GA21 are herbicide tolerance and insect
resistance, with no intention to alter the nutritional parameters. However, the levels of b-carotene,
b-cryptoxanthin and lutein measured in the ﬁeld trials in 2016 in both treated and non-treated GM
maize were signiﬁcantly different from its non-GM comparator and showed a lack of equivalence with
the reference varieties (Section 3.3.2.3). The biological role of these compounds, their levels in maize
and maize-derived products and the magnitude and direction of the observed changes were
considered during the nutritional assessment.
Human nutrition
Levels of b-carotene and b-cryptoxanthin in both treated and non-treated maize
Bt11 9 MIR162 9 1507 9 GA21 analysed in the ﬁeld trials carried out in 2016 were lower than those
reported for the non-GM comparator: about 50% lower for b-carotene and about 40% lower for b-
cryptoxanthin (Section 3.3.2.3). Both carotenoids are precursors of vitamin A and are found in plant-
derived foods; together with preformed vitamin A (mainly retinol and retinyl esters) present in foods of
animal origin, they contribute to the total dietary intake of vitamin A. Milk, meat, vegetables and
derived products are the main sources of vitamin A in the diet (EFSA NDA Panel, 2015). Cereals and
cereal-based products contribute much less to the total intake of vitamin A, with contributions in the
adult population ranging between 2.7% and 6.5% of the total (average contribution = 4.1%), with the
maximum contribution (10%) estimated in adolescents (EFSA NDA Panel, 2015). Similar contribution
by cereals and cereal-based products is observed in the young population (toddlers, 1–3 years old)
with up to 7% of total vitamin A intake. In this age class, there are speciﬁcally manufactured foods
(‘Food products for young population’) that are supplemented with vitamin A in order to reach the
regulated levels;42,43 in most cases, they are supplemented with preformed vitamin A (retinol) rather
than with b-carotene. The contribution of these foods to the total vitamin A intake can be up to 16%
(EFSA NDA Panel, 2015).
Levels of lutein in both treated and non-treated maize Bt11 9 MIR162 9 1507 9 GA21 were about
35% lower than those reported for the non-GM comparator. Unlike for vitamin A, no recommended
dietary intake levels for lutein have been established, as the evidence provided is insufﬁcient to
establish a cause–effect relationship between consumption of lutein and maintenance of normal vision
(EFSA NDA Panel, 2010, 2012). Lutein is together with zeaxanthin the dominant carotenoid in maize
kernels, although their levels are much lower than those identiﬁed in green leafy vegetables such as
spinach, kale and parsley (Humphries and Khachik, 2003; Abdel-Aal et al., 2013; Eisenhauer et al.,
2017). Even though in most current nutrition databases the content of lutein is given together with
zeaxanthin, it is known that, in general, zeaxanthin and not lutein is the predominant carotenoid in
maize and maize-based products, while the opposite is observed in green leafy vegetables (Humphries
and Khachik, 2003; Perry et al., 2009).
Although a signiﬁcantly lower level of b-carotene and b-cryptoxanthin was observed in maize
Bt11 9 MIR162 9 1507 9 GA21 compared to its non-GM comparator, the current available consumption
data indicate a minor contribution of maize and maize-derived products to total vitamin A intake. Based
on this, the GMO Panel concludes that foods derived from maize Bt11 9 MIR162 9 1507 9 GA21 have
the same nutritional impact as regards the total vitamin A intake as those derived from its non-GM
comparator and the non-GM commercial reference varieties. Similarly, due to the current contribution of
maize and maize-derived products to the total dietary intake of lutein and considering the unproven
beneﬁcial effects of lutein on health, the GMO Panel concludes that no adverse effects on human nutrition
from the consumption of maize Bt11 9 MIR162 9 1507 9 GA21 can be expected.
Animal nutrition
Considering that the signiﬁcance of b-carotene/b-cryptoxanthin in diets for animals is negligible
because these are supplemented with vitamin A, the GMO Panel is of the view that the observed lower
level of b-carotene in maize Bt11 9 MIR162 9 1507 9 GA21 would not affect its total dietary intake in
the European animal population. Other carotenoids, such as lutein and zeaxanthin, are used as
41 Dossier: Part I – Section D7.10.
42 COMMISSION DIRECTIVE 2006/141/EC of 22 December 2006 on infant formulae and follow-on formulae and amending
Directive 1999/21/EC.
43 COMMISSION DIRECTIVE 2006/125/EC of 5 December 2006 on processed cereal-based foods and baby foods for infants and
young children.
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colourants in poultry for yolk and skin colouring (EFSA, 2009c), but are not recognised as essential
nutrients for animals.
3.3.3.6. Conclusion
The GMO Panel considers that the newly expressed proteins in the four-event stack maize do not
raise safety concerns for human and animal health and that, on the basis of the biological properties
of the newly expressed proteins, no interactions relevant to food and feed are expected between these
proteins. The GMO Panel did not identify safety concerns regarding allergenicity or adjuvanticity with
the presence of newly expressed proteins in this four-event stack maize, or regarding the overall
allergenicity of the four-event stack maize. The GMO Panel concludes that foods and feeds derived
from maize Bt11 9 MIR162 9 1507 9 GA21 are expected to have the same nutritional impact as
those derived from non-GM commercial maize varieties.
3.3.4. Environmental risk assessment44
Considering the scope of application EFSA-GMO-DE-2010-86, which excludes cultivation, the ERA of
maize Bt11 9 MIR162 9 1507 9 GA21 mainly takes into account: (1) exposure of microorganisms to
recombinant DNA in the gastrointestinal tract of animal fed GM material and of microorganisms
present in environments exposed to faecal material of these animals (manure and faeces); and (2) the
accidental release into the environment of viable maize Bt11 9 MIR162 9 1507 9 GA21 grains during
transportation and processing (EFSA GMO Panel, 2010a).
3.3.4.1. Persistence and invasiveness of the GM plant45
Maize is highly domesticated, not winter hardy in colder regions of Europe and generally unable to
survive in the environment without appropriate management. Occasional feral GM maize plants may
occur outside cultivation areas in the EU (e.g. Pascher, 2016), but survival is limited mainly by a
combination of low competitiveness, absence of a dormancy phase and susceptibility to plant pathogens,
herbivores and cold climate conditions (OECD, 2003). Field observations indicate that maize grains may
survive and overwinter in some EU regions, resulting in volunteers in subsequent crops (e.g. Gruber
et al., 2008; Palaudelmas et al., 2009; Pascher, 2016). However, maize volunteers have been shown to
grow weakly and ﬂower asynchronously with the maize crop (Palaudelmas et al., 2009). Thus, the
establishment and survival of feral and volunteer maize in the EU is currently limited and transient.
It is unlikely that the intended traits of maize Bt11 9 MIR162 9 1507 9 GA21 will provide a
selective advantage to maize plants, except when they are exposed to glyphosate- and/or glufosinate-
ammonium-containing herbicides or infested by insect pests that are susceptible to the Cry1Ab, Cry1F
and/or Vip3Aa20 proteins.
The GMO Panel considers that the ﬁtness advantage provided by the intended traits, and the
observed differences in emerged plants, heat units to 50% silking and 50% pollen shed (see
Section 3.3.2.2) will not allow the GM plant to overcome other biological and abiotic factors (described
above) limiting plant’s persistence and invasiveness. Therefore, the presence of the intended traits and
other observed differences will not affect the persistence and invasiveness of the GM plant.
In conclusion, the GMO Panel considers it very unlikely that maize Bt11 9 MIR162 9 1507 9 GA21
will differ from conventional maize hybrid varieties in its ability to survive until subsequent seasons or
to establish occasional feral plants under European environmental conditions in case of accidental
release into the environment of viable maize Bt11 9 MIR162 9 1507 9 GA21 grains.
3.3.4.2. Potential for gene transfer46
A prerequisite for any gene transfer is the availability of pathways for the transfer of genetic
material, either through horizontal gene transfer (HGT) of DNA or through vertical gene ﬂow via cross-
pollination from feral plants originating from spilled grains.
Plant-to-microorganism gene transfer
The probability and potential adverse effects of HGT of the recombinant DNA have been assessed
in the previous GMO Panel Scientiﬁc Opinions on the single events (see Table 2). No concern as a
result of an unlikely, but theoretically possible, HGT of the recombinant genes to bacteria in the gut of
44 Dossier: Part I – Section D9.
45 Dossier: Part I – Section D9.1 and D9.2.
46 Dossier: Part I – Section D9.3.
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domesticated animals and humans fed GM material or other receiving environments was identiﬁed.
Synergistic effects of the recombinant genes, for instance due to combinations of recombinogenic
sequences, which would cause an increase in the likelihood for HGT or a selective advantage were not
identiﬁed. Therefore, the GMO Panel concludes that the unlikely, but theoretically possible, horizontal
transfer of recombinant genes from this four-event stack maize to bacteria does not raise any
environmental safety concern.
Plant-to plant-gene transfer
The potential for occasional feral maize Bt11 9 MIR162 9 1507 9 GA21 plants originating from
grain import spills to transfer recombinant DNA to sexually compatible plants and the environmental
consequences of this transfer were considered.
For plant-to-plant gene transfer to occur, imported GM maize grains need to germinate and develop
into plants in areas containing sympatric wild relatives and/or cultivated maize with synchronous
ﬂowering and environmental conditions favouring cross-pollination.
Maize is an annual predominantly cross-pollinating crop. Cross-fertilisation occurs mainly by wind
(OECD, 2003). Vertical gene transfer from maize is limited to Zea species. Wild relatives of maize
outside cultivation are not known/reported in Europe (Eastham and Sweet, 2002; OECD, 2003; EFSA,
2016; Trtikova et al., 2017). Therefore, potential vertical gene transfer is restricted to maize and
weedy Zea species, such as teosintes and/or maize–teosinte hybrids, occurring in cultivated areas
(EFSA, 2016; Trtikova et al., 2017).
The potential of spilled maize grains to establish, grow and produce pollen is extremely low and
transient (see Section 3.3.4.1). Therefore, the likelihood/frequency of cross-pollination between
occasional feral GM maize plants resulting from grain spillage and weedy or cultivated Zea plants is
considered extremely low (EFSA, 2016). Even if cross-pollination would occur, the GMO Panel is of the
opinion that environmental effects as a consequence of the spread of genes from occasional feral GM
maize plants in Europe will not differ from that of conventional maize varieties, for the reasons given in
Section 3.3.4.1.
3.3.4.3. Interactions of the GM plant with target organisms47
Taking the scope of application EFSA-GMO-DE-2010-86 into account, potential interactions of
occasional feral maize Bt11 9 MIR162 9 1507 9 GA21 plants with the target organism arising from
grain import spills are not considered a relevant issue.
3.3.4.4. Interactions of the GM plant with non-target organisms48
Given that environmental exposure of non-target organisms to spilled GM grains or occasional feral
GM maize plants arising from spilled maize Bt11 9 MIR162 9 1507 9 GA21 grains is limited, and
because ingested proteins are degraded before entering the environment through faecal material of
animals fed GM maize, potential interactions of maize Bt11 9 MIR162 9 1507 9 GA21 with non-target
organisms are not considered to raise any environmental safety concern. Interactions that may occur
between the Cry and Vip proteins (as mentioned in Section 3.3.1.1) will not alter this conclusion.
3.3.4.5. Interactions with the abiotic environment and biogeochemical cycles49
Given that environmental exposure to spilled grains or occasional feral maize Bt11 9 MIR162 9 1507
9 GA21 plants arising from grain import spills is limited, and because ingested proteins are degraded
before entering the environment through faecal material of animals fed GM maize, potential interactions
with the abiotic environment and biogeochemical cycles are not considered to raise any environmental
safety concern.
3.3.4.6. Conclusion of the environmental risk assessment
The GMO Panel concludes that it is unlikely that maize Bt11 9 MIR162 9 1507 9 GA21 would
differ from conventional maize varieties in its ability to persist under European environmental
conditions. Considering the scope of application EFSA-GMO-DE-2010-86, interactions of occasional feral
maize Bt11 9 MIR162 9 1507 9 GA21 plants with the biotic and abiotic environment are not
considered to be relevant issues. The analysis of HGT from maize Bt11 9 MIR162 9 1507 9 GA21 to
47 Dossier: Part I – Section D9.4.
48 Dossier: Part I – Section D9.5.
49 Dossier: Part I – Section D9.8.
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bacteria does not indicate a safety concern. Therefore, considering the combined traits and their
interactions, the outcome of the comparative analysis and the routes and levels of exposure, the GMO
Panel concludes that maize Bt11 9 MIR162 9 1507 9 GA21 would not raise safety concerns in the
event of accidental release of viable GM maize grains into the environment.
3.3.5. Conclusion on maize Bt11 3 MIR162 3 1507 3 GA21
No new data on the single maize events Bt11, MIR162, 1507 and GA21 leading to a modiﬁcation of
the original conclusions on their safety were identiﬁed.
Based on the molecular characterisation and on the comparative analysis of agronomic, phenotypic
and compositional characteristics, the combination of maize events Bt11, MIR162, 1507 and GA21 in
the four-event stack maize did not give rise to food and feed safety issues. Based on the nutritional
assessment of the compositional characteristics of maize Bt11 9 MIR162 9 1507 9 GA21, foods and
feeds derived from the GM maize are expected to have the same nutritional impact as those derived
from non-GM maize varieties.
The newly expressed proteins in the four-event stack maize do not raise safety concerns for human
and animal health and the environment, in light of the scope of this application.
Based on the biological functions of the newly expressed proteins, no indications of interactions
between the events were identiﬁed that would raise a safety issue. Comparison of the levels of the
newly expressed proteins between the four-event stack and each of the single events did not reveal an
interaction at protein expression level.
Considering the combined traits and their interactions, the outcome of the comparative analysis and
routes and levels of exposure, the GMO Panel concludes that maize Bt11 9 MIR162 9 1507 9 GA21
would not raise safety concerns in the event of accidental release of viable GM maize grains into the
environment.
No scientiﬁc information that could change the conclusions on this four-event stack was retrieved in
a literature search covering the period since the time of validity of the application.50
The GMO Panel concludes that the four-event stack maize is nutritionally equivalent to and as safe
as its non-GM comparator in the context of the scope of this application.
3.4. Risk assessment of the subcombinations
3.4.1. Subcombinations previously assessed
In previous assessments, the GMO Panel identiﬁed no safety concerns for the seven
subcombinations of maize Bt11 9 MIR162 9 1507 9 GA21 not included in the scope of application
EFSA-GMO-DE-2010-86 (Table 2). No new scientiﬁc information relevant to the risk assessment of
these subcombinations became available since the validation of the application. Consequently, the
GMO Panel considers that its previous conclusions on these subcombinations remain valid.
3.4.2. Subcombinations not previously assessed
The three subcombinations of maize Bt11 9 MIR162 9 1507 9 GA21 included in the scope of this
application have not been previously assessed: the three-event stacks MIR162 9 1507 9 GA21 and
Bt11 9 MIR162 9 1507 and the two-event stack MIR162 9 1507 (Table 1). No experimental data
were provided for these maize stacks. The strategy followed for the assessment of subcombinations
for which no speciﬁc data have been submitted, and which have not been previously assessed, has
been described by the GMO Panel.51 The risk assessment takes as its starting point the assessment of
the single maize events and uses the data generated for the four-event stack as well as all the
additional data available on subcombinations previously assessed by the GMO Panel.
A literature search revealed no scientiﬁc information relevant to the risk assessment of the three
subcombinations that became available since the validation of application EFSA-GMO-DE-2010-86.50
3.4.2.1. Stability of the events
The genetic stability of the inserted DNA over multiple generations in the four single maize events
was demonstrated previously (see Table 2). Integrity of the events was demonstrated in the four-event
50 Additional information: 3/11/2016.
51 115th GMO Panel meeting (Annex 1 of the minutes: http://www.efsa.europa.eu/sites/default/files/event/170517-m.pdf).
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stack Bt11 9 MIR162 9 1507 9 GA21 (Section 3.3.1) and in the previously assessed subcombinations
(Table 2). The GMO Panel ﬁnds no reasons to expect loss of integrity of the events in the
subcombinations MIR162 9 1507 9 GA21, Bt11 9 MIR162 9 1507 and MIR162 9 1507.
3.4.2.2. Expression of the events
The GMO Panel assessed whether the combination of any of the four events by conventional
crossing could result in signiﬁcant changes in expression levels of the newly expressed proteins, as this
could indicate an interaction between the events present in the three subcombinations. Based on
current knowledge of the molecular elements introduced, there is no reason to expect interactions that
would affect the levels of the newly expressed proteins in the subcombinations compared with those in
the single maize events. This assumption was conﬁrmed by comparing the levels of the newly
expressed proteins of each single maize event with those of the four-event stack maize. The levels
were similar in the four-event stack maize and in the single events, except for the differences observed
for Cry1Ab in leaves and for the expected differences in PAT levels resulting from the combination of
the Bt11 and 1507 events both producing PAT protein (Section 3.3.1.3 and Appendix A). Therefore,
there is no indication of an interaction manifesting at protein expression level. In addition, protein
expression data from the two-event stacks Bt11 9 GA21 (EFSA GMO Panel, 2009a) and
Bt11 9 MIR162 (EFSA GMO Panel, 2017c) and the three-event stack Bt11 9 1507 9 GA21 (EFSA
GMO Panel, 2017d) were either similar to those observed in each of the single maize events or, for PAT
in maize Bt11 9 1507 9 GA21, showed the expected higher levels resulting from the combination of
the Bt11 and 1507 events, both producing PAT protein. This conﬁrms that interactions affecting
expression levels of the newly expressed proteins are not expected in the subcombinations
MIR162 9 1507 9 GA21, Bt11 9 MIR162 9 1507 and MIR162 9 1507 included in the scope of this
application.
3.4.2.3. Potential interactions between the events
The GMO Panel assessed the potential interactions between events due to their combination in
maize MIR162 9 1507 9 GA21, maize Bt11 9 MIR162 9 1507 and maize MIR162 9 1507, taking into
consideration intended traits and identiﬁed potential unintended effects.
Based on the known biological functions of the individual newly expressed proteins (Table 4), there
is currently no expectation for possible interactions relevant for the food/feed or environmental safety
between these proteins in any of the three subcombinations, taking into account the scope of this
application.
The GMO Panel took into account the intended and potential unintended effects considered in the
assessment of the four single events, of the previously assessed subcombinations (Table 2) and of the
four-event stack maize Bt11 9 MIR162 9 1507 9 GA21. It was concluded that none of these effects
would raise safety concerns when combined in any of the three maize subcombinations. Therefore, the
GMO Panel is of the opinion that no additional data are needed to complete the assessment of the
three subcombinations.
3.4.3. Conclusion
For the three subcombinations included in the scope of application EFSA-GMO-DE-2010-86, no
experimental data have been provided. The GMO Panel assessed the possibility of interactions between
the events and concluded that these combinations do not raise safety concerns. The three
subcombinations are therefore expected to be as safe as the single maize events, the previously
assessed subcombinations (Table 2) and the four-event stack maize Bt11 9 MIR162 9 1507 9 GA21.
3.5. Post-market monitoring
3.5.1. Post-market monitoring of GM food/feed52
No compositional changes relevant for food/feed safety or nutrition were identiﬁed in maize
Bt11 9 MIR162 9 1507 9 GA21 when compared with the non-GM comparator. The GMO Panel considers
maize Bt11 9 MIR162 9 1507 9 GA21 to be as safe as the non-GM comparator. The three
subcombinations not previously assessed and included in the scope of application EFSA-GMO-DE-2010-86
are expected to be as safe as the single maize events, the four-event stack maize
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Bt11 9 MIR162 9 1507 9 GA21 and the previously assessed subcombinations. Therefore, the GMO
Panel considers that post-market monitoring (EFSA, 2006) of food/feed derived from maize
Bt11 9 MIR162 9 1507 9 GA21 and its three subcombinations is not necessary.
3.5.2. Post-market environmental monitoring53
The objectives of a PMEM plan according to Annex VII of Directive 2001/18/EC are: (1) to conﬁrm
that any assumption regarding the occurrence and impact of potential adverse effects of the GMO, or
its use, in the ERA are correct and (2) to identify the occurrence of adverse effects of the GMO, or its
use, on human health or the environment that were not anticipated in the ERA.
Monitoring is related to risk management, and thus, a ﬁnal adoption of the PMEM plan falls outside
the mandate of EFSA. However, the GMO Panel gives its opinion on the scientiﬁc rationale of the PMEM
plan provided by the applicant (EFSA GMO Panel, 2011b).
As the ERA did not identify potential adverse environmental effects from maize
Bt11 9 MIR162 9 1507 9 GA21 (Section 3.3.4), no case-speciﬁc monitoring is required.
The PMEM plan proposed by the applicant for maize Bt11 9 MIR162 9 1507 9 GA21 includes (1)
the description of a monitoring approach involving operators (federations involved in import and
processing), reporting to applicant, via a centralised system, any observed adverse effect(s) of GMOs
on human health and the environment; (2) a coordinating system established by EuropaBio for the
collection of the information recorded by the various operators; and (3) review of relevant scientiﬁc
publications retrieved from literature searches (Lecoq et al., 2007; Windels et al., 2008). The applicant
proposes to submit a PMEM report on an annual basis and a ﬁnal report at the end of the
authorisation period. The GMO Panel considers that the scope of the PMEM plan provided by the
applicant is consistent with the intended uses of maize Bt11 9 MIR162 9 1507 9 GA21. The GMO
Panel agrees with the reporting intervals proposed by the applicant in its PMEM plan.
4. Overall conclusions and recommendations
No new information on the single maize events Bt11, MIR162, 1507 and GA21 that would lead to a
modiﬁcation of the original conclusions on their safety were identiﬁed.
The combination of events Bt11, MIR162, 1507 and GA21 in the four-event stack maize did not give
rise to issues relating to molecular, agronomic/phenotypic and compositional characteristics regarding
food and feed safety. The newly expressed proteins in the four-event stack maize did not raise concerns
for human and animal health. Foods and feeds from maize Bt11 9 MIR162 9 1507 9 GA21 are
expected to have the same nutritional impact as those derived from the non-GM comparator.
The GMO Panel concluded that there is a very low likelihood of environmental effects resulting from
the accidental release of viable grains from maize Bt11 9 MIR162 9 1507 9 GA21 into the environment.
The GMO Panel concludes that maize Bt11 9 MIR162 9 1507 9 GA21 is nutritionally equivalent to
and as safe as its non-GM comparator in the context of the scope of this application.
The three subcombinations included in the scope of this application were not previously assessed.
For these subcombinations, for which no experimental data were provided, the GMO Panel assessed
the possibility of interactions between the events and concluded that these combinations would not
raise safety concerns. The three subcombinations not previously assessed are expected to be as safe
as the single maize events, the previously assessed subcombinations and the four-event stack maize
Bt11 9 MIR162 9 1507 9 GA21.
Given that no safety concerns were identiﬁed for food and feed derived from maize
Bt11 9 MIR162 9 1507 9 GA21 and its three subcombinations, the GMO Panel considers that post-
market monitoring of these products is not necessary. The post-market environmental monitoring plan
and reporting intervals are in line with the intended uses of maize Bt11 9 MIR162 9 1507 9 GA21
and its three subcombinations.
A minority opinion expressed by a GMO Panel member is presented in Appendix B.
Documentation as provided to EFSA
1) Letter from the Competent Authority of Germany, dated 10 August 2010, concerning a
request for placing on the market of maize Bt11 9 MIR162 9 1507 9 GA21 in accordance
with Regulation (EC) No 1829/2003.
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2) Acknowledgement letter, dated 27 September 2010, from EFSA to the Competent Authority
of Germany.
3) Letter from EFSA to applicant, dated 11 October 2010, requesting additional information
under completeness check.
4) Letter from applicant to EFSA, received on 26 January 2011, providing additional
information under completeness check.
5) Letter from EFSA to applicant, dated 4 March 2011, requesting additional information under
completeness check.
6) Letter from applicant to EFSA, received on 25 March 2011, providing additional information
under completeness check.
7) Letter from applicant to EFSA, received on 04 July 2011, extending the timeline for
responses.
8) Letter from applicant to EFSA, received on 12 December 2011, extending the timeline for
responses.
9) Letter from applicant to EFSA, received on 21 December 2011, providing additional
information under completeness check.
10) Letter from EFSA to applicant, dated 25 January 2012, requesting additional information
under completeness check.
11) Letter from applicant to EFSA, received on 15 March 2012, clarifying the scope of the
application.
12) Letter from applicant to EFSA, received on 02 April 2012, providing additional information
under completeness check. Letter from EFSA to applicant, dated 6 June 2012, conﬁrming
the scope of the application.
13) Letter from EFSA to applicant, dated 14 June 2012, delivering the ‘Statement of Validity’
for application EFSA-GMO-DE-2010-86, maize Bt11 9 MIR162 9 1507 9 GA21 submitted
by Syngenta under Regulation (EC) No 1829/2003.
14) Letter from EFSA to applicant dated 31 October 2012 requesting additional information and
stopping the clock on behalf of the EURL-GMFF.
15) Letter from EFSA to applicant dated 7 December 2012 requesting additional information
and maintaining the clock stopped.
16) Letter from EFSA to applicant dated 13 December 2012 re-starting the clock on behalf of
the EURL-GMFF and maintaining the clock stopped by EFSA.
17) Letter from EFSA to applicant, dated 5 February 2013, requesting additional information.
18) Letter from applicant to EFSA, received on 26 April 2013, providing additional information.
19) Letter from EFSA to applicant, dated 27 September 2013, requesting additional information
and maintaining the clock stopped.
20) Letter from applicant to EFSA, received on 04 November 2013, extending the timeline for
responses.
21) Letter from applicant to EFSA, received on 18 February 2014, redeﬁning the scope of the
application.
22) Letter from EFSA to applicant dated 4 June 2014 requesting additional information and
maintaining the clock stopped.
23) Letter from applicant to EFSA, received on 10 June 2014, extending the timeline for
responses.
24) Letter from applicant to EFSA, received on 16 June 2014, providing additional information.
25) Letter from applicant to EFSA, received on 23 June 2014, providing additional information.
26) Letter from applicant to EFSA, received on 28 July 2014, spontaneously providing
additional information.
27) Letter from EFSA to applicant, dated 16 September 2014, requesting additional information
and maintaining the clock stopped.
28) Letter from applicant to EFSA, received on 30 September 2014, providing additional
information.
29) Letter from EFSA to applicant, dated 3 October 2014, requesting additional information
and maintaining the clock stopped.
30) Letter from EFSA to applicant, dated 10 November 2014, requesting additional information
and maintaining the clock stopped.
31) Letter from applicant to EFSA, received on 21 November 2014, providing additional
information.
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32) Letter from applicant to EFSA, received on 28 November 2014, providing additional
information.
33) Letter from applicant to EFSA, dated 23 December 2014, extending the timeline for
responses.
34) Letter from applicant to EFSA, received on 12 March 2015, providing additional
information.
35) Letter from applicant to EFSA received on 27 May 2015 asking for clariﬁcations on the
additional information requested by EFSA on 10 November 2015.
36) Letter from EFSA to applicant dated 17 June 2015 providing clariﬁcations requested on 27
May 2015.
37) Letter from applicant to EFSA, received on 21 July 2015, providing sequencing information
spontaneously.
38) Letter from applicant to EFSA, received on 30 July 2015 (resubmitted on 10 August 2015),
providing additional information.
39) Letter from applicant to EFSA, received on 9 September 2015, spontaneously providing
additional information.
40) Letter from EFSA to applicant, dated 22 September 2015, requesting additional information
and maintaining the clock stopped.
41) Letter from applicant to EFSA, received on 24 September 2015, providing additional
information.
42) Letter from EFSA to applicant, dated 23 October 2015, restarting the clock.
43) Letter from applicant to EFSA, received on 8 December 2015, redeﬁning the scope of the
application.
44) Letter from applicant to EFSA, received on 17 December 2015, spontaneously providing
additional information.
45) Letter from EFSA to applicant, dated 23 December 2015, requesting additional information
and stopping the clock.
46) Letter from applicant to EFSA, received on 4 April 2016, redeﬁning the scope of the
application.
47) Letter from applicant to EFSA, received on 4 April 2016, providing additional information.
48) E-mail from EFSA to applicant, dated 11 April 2016, restarting the clock from 4 April 2016.
49) Letter from EFSA to applicant, dated 4 August 2016, requesting additional information and
stopping the clock.
50) Letter from applicant to EFSA, received on 3 November 2016, providing additional
information.
51) E-mail from EFSA to applicant, dated 4 November 2016, restarting the clock from 3
November 2016
52) Letter from applicant to EFSA, received on 25 November 2016, spontaneously providing
additional information.
53) Letter from EFSA to applicant, dated 1 February 2017, requesting additional information
and stopping the clock.
54) Letter from applicant to EFSA, dated 16 March 2017, extending the timeline for responses.
55) Letter from EFSA to applicant, dated 18 May 2017, requesting additional information and
maintaining the clock stopped.
56) Letter from applicant to EFSA, received on 12 June 2017, providing additional information.
57) Letter from applicant to EFSA, dated 3 July 2017, extending the timeline for responses.
58) Letter from applicant to EFSA, received on 4 October 2017, spontaneously providing
additional information.
59) Letter from applicant to EFSA, received on 14 December 2017, providing additional
information.
60) E-mail from EFSA to applicant, dated 18 December 2017, restarting the clock from 14
December 2017.
61) Letter from EFSA to applicant, dated 20 December 2017, requesting additional information
and stopping the clock.
62) Letter from EFSA to applicant, dated 18 January 2018, requesting additional information
and maintaining the clock stopped.
63) Letter from applicant to EFSA, dated 2 February 2018, extending the timeline for
responses.
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64) Letter from EFSA to applicant, dated 16 February 2018, requesting additional information
and maintaining the clock stopped.
65) Letter from applicant to EFSA, received on 5 March 2018, providing additional information.
66) Letter from applicant to EFSA, received on 5 April 2018, providing additional information.
67) Letter from applicant to EFSA, received on 30 April 2018, providing additional information.
68) E-mail from EFSA to applicant, dated 30 April 2018, restarting the clock.
References
Abdel-Aal ESM, Akhtar H, Zaheer K and Ali R, 2013. Dietary sources of lutein and zeaxanthin carotenoids and their
role in eye health. Nutrients, 5, 1169–1185.
Alimentarius Codex, 2009. Foods derived from modern biotechnology. Codex Alimentarius Commission, Joint FAO/
WHO Food Standards Programme. Rome, Italy. p. 85.
Droge-Laser W, Siemeling U, Puhler A and Broer I, 1994. The Metabolites of the Herbicide L-Phosphinothricin
(Glufosinate) (Identiﬁcation, Stability, and Mobility in Transgenic, Herbicide-Resistant, and Untransformed
Plants). Plant Physiology, 105, 159–166.
Eastham K and Sweet J, 2002. Genetically modiﬁed organisms (GMOs): the signiﬁcance of gene ﬂow through
pollen transfer. Environmental Issue Report No 28. European Environment Agency, Copenhagen, Denmark.
Available online: http://www.eea.europa.eu/publications/environmental_issue_report_2002_28
EFSA (European Food Safety Authority), 2004. Opinion of the Scientiﬁc Panel on Genetically Modiﬁed Organisms
on a request from the Commission related to the Notiﬁcation (Reference C/NL/00/10) for the placing on the
market of insect-tolerant genetically modiﬁed maize 1507, for import and processing, under Part C of Directive
2001/18/EC from Pioneer Hi-Bred International/Mycogen Seeds. EFSA Journal 2004;2(10):124, 18 pp. https://
doi.org/10.2903/j.efsa.2004.124
EFSA (European Food Safety Authority), 2005a. Opinion of the Panel on Genetically Modiﬁed Organisms (GMO
Panel) on a request from the Commission related to the notiﬁcation (Reference C/F/96/05.10) for the placing
on the market of insect-tolerant genetically modiﬁed maize Bt11, for cultivation, feed and industrial processing,
under Part C of Directive 2001/18/EC from Syngenta Seeds. EFSA Journal 2005;3(5):213, 33 pp. https://doi.
org/10.2903/j.efsa.2005.213
EFSA (European Food Safety Authority), 2005b. Opinion of the Scientiﬁc Panel on Genetically Modiﬁed Organisms
on a request from the Commission related to the notiﬁcation (Reference C/ES/01/01) for the placing on the
market of insect-tolerant genetically modiﬁed maize 1507, for import, feed and industrial processing and
cultivation, under Part C of Directive 2001/18/EC from Pioneer Hi-Bred International/Mycogen Seeds. EFSA
Journal 2005;3(3):181, 33 pp. https://doi.org/10.2903/j.efsa.2005.181
EFSA (European Food Safety Authority), 2005c. Opinion of the Scientiﬁc Panel on Genetically Modiﬁed Organisms
on an application (reference EFSA-GMO-NL-2004-02) for the placing on the market of insect-tolerant genetically
modiﬁed maize 1507, for food use, under Regulation (EC) No 1829/2003 from Pioneer Hi-Bred International/
Mycogen Seeds. EFSA Journal 2005;3(3):182, 22 pp. https://doi.org/10.2903/j.efsa.2005.182
EFSA (European Food Safety Authority), 2006. Guidance Document of the Panel on Genetically Modiﬁed Organisms
(GMO Panel) for the risk assessment of genetically modiﬁed plants and derived food and feed. EFSA Journal
2006;4(4):99, 100 pp. https://doi.org/10.2903/j.efsa.2006.99
EFSA (European Food Safety Authority), 2007a. Guidance document of the Panel on Genetically Modiﬁed Organisms
(GMO Panel) on genetically modiﬁed organisms for the risk assessment of genetically modiﬁed plants containing
stacked transformation events. EFSA Journal 2007;5(7):512, 5 pp. https://doi.org/10.2903/j.efsa.2007.512
EFSA (European Food Safety Authority), 2007b. Opinion of the Panel on Genetically Modiﬁed Organisms (GMO
Panel) on application (Reference EFSA-GMO-UK-2005-19 and EFSA-GMO-RX-GA21) for the placing on the
market of glyphosate-tolerant genetically modiﬁed maize GA21, for food and feed uses, import and processing
and for renewal of the authorisation of maize GA21 as existing product, both under Regulation (EC) No 1829/
2003 from Syngenta Seeds S.A.S. on behalf of Syngenta Crop Protection AG. EFSA Journal 2007;5(10):541, 25
pp. https://doi.org/10.2903/j.efsa.2007.541
EFSA (European Food Safety Authority), 2009a. Opinion of the Panel on Genetically Modiﬁed Organisms (GMO
Panel) on application reference EFSA-GMO-RX-Bt11 for renewal of the authorisation of existing products
produced from insect-resistant genetically modiﬁed maize Bt11, under Regulation (EC) No 1829/2003 from
Syngenta. EFSA Journal 2009;7(2):977, 13 pp. https://doi.org/10.2903/j.efsa.2009.977
EFSA (European Food Safety Authority), 2009b. Scientiﬁc Opinion of the Panel on Genetically Modiﬁed Organisms on
Application (EFSA-GMO-RX-1507) for renewal of authorisation for the continued marketing of existing products
produced from maize 1507 for feed use, under Regulation (EC) No 1829/2003 from Pioneer Hi-Bred International,
Inc./Mycogen Seeds. EFSA Journal 2009;7(6):1138, 11 pp. https://doi.org/10.2903/j.efsa.2009.1138
EFSA (European Food Safety Authority), 2009c. Scientiﬁc Opinion of the Panel on Additives and Products or
Substances used in Animal Feed (FEEDAP) on a request from the European Commission on the safety of use of
colouring agents in animal nutrition (Part III). EFSA Journal 2009;7(5):1098, 49 pp. https://doi.org/10.2903/
j.efsa.2009.1098
Assessment of maize Bt11 x MIR162 x 1507 x GA21 and subcombinations
www.efsa.europa.eu/efsajournal 26 EFSA Journal 2018;16(7):5309
EFSA (European Food Safety Authority), 2016. Relevance of new scientiﬁc evidence on the occurrence of teosinte
in maize ﬁelds in Spain and France for previous environmental risk assessment conclusions and risk
management recommendations on the cultivation of maize events MON810, Bt11, 1507 and GA21. EFSA
supporting publication 2016:EN-1094. 13 pp. Available online: http://www.efsa.europa.eu/en/supporting/pub/
en-1094
EFSA GMO Panel (EFSA Panel on Genetically Modiﬁed Organisms), 2009a. Scientiﬁc Opinion on application (Reference
EFSA-GMO-UK-2007-49) for the placing on the market of insect resistant and herbicide tolerant genetically
modiﬁed maize Bt11xGA21, for food and feed uses, import and processing under Regulation (EC) No 1829/2003
from Syngenta Seeds. EFSA Journal 2009;7(9):1319, 27 pp. https://doi.org/10.2903/j.efsa.2009.1319
EFSA GMO Panel (EFSA Panel on Genetically Modiﬁed Organisms), 2010a. Guidance on the environmental risk
assessment of genetically modiﬁed plants. EFSA Journal 2010;8(11):1879, 111 pp. https://doi.org/10.2903/j.ef
sa.2010.1879
EFSA GMO Panel (EFSA Panel on Genetically Modiﬁed Organisms), 2010b. Statistical considerations for the safety
evaluation of GMOs. EFSA Journal 2010;8(1):1250, 59 pp. https://doi.org/10.2903/j.efsa.2010.1250
EFSA GMO Panel (EFSA Panel on Genetically Modiﬁed Organisms), 2011a. Guidance for risk assessment of food
and feed from genetically modiﬁed plants. EFSA Journal 2011;9(5):2150, 37 pp. https://doi.org/10.2903/j.efsa.
2011.2150
EFSA GMO Panel (EFSA Panel on Genetically Modiﬁed Organisms), 2011b. Guidance on the post-market
environmental monitoring (PMEM) of genetically modiﬁed plants. EFSA Journal 2011;9(8):2316, 40 pp.
https://doi.org/10.2903/j.efsa.2011.2316
EFSA GMO Panel (EFSA Panel on Genetically Modiﬁed Organisms), 2012a. Scientiﬁc Opinion updating the risk
assessment conclusions and risk management recommendations on the genetically modiﬁed insect resistant
maize Bt11. EFSA Journal 2012;10(12):3018, 104 pp. https://doi.org/10.2903/j.efsa.2012.3018
EFSA GMO Panel (EFSA Panel on Genetically Modiﬁed Organisms), 2012b. Scientiﬁc Opinion on application (EFSA-
GMO-DE-2010-82) for the placing on the market of insect-resistant genetically modiﬁed maize MIR162 for food
and feed uses, import and processing under Regulation (EC) No 1829/2003 from Syngenta. EFSA Journal
2012;10(6):2756, 27 pp. https://doi.org/10.2903/j.efsa.2012.2756
EFSA GMO Panel (EFSA Panel on Genetically Modiﬁed Organisms), 2012c. Scientiﬁc Opinion updating the risk
assessment conclusions and risk management recommendations on the genetically modiﬁed insect resistant
maize 1507. EFSA Journal 2012;10(10):2933, 46 pp. https://doi.org/10.2903/j.efsa.2012.2933
EFSA GMO Panel (EFSA Panel on Genetically Modiﬁed Organisms), 2015a. Scientiﬁc Opinion on an application by
Syngenta (EFSA-GMO-DE-2009-66) for placing on the market of herbicide tolerant and insect resistant maize
Bt11 9 MIR162 9 MIR604 9 GA21 and subcombinations independently of their origin for food and feed uses,
import and processing under Regulation (EC) No 1829/2003. EFSA Journal 2015;13(12):4297, 34 pp. https://
doi.org/10.2903/j.efsa.2015.4297
EFSA GMO Panel (EFSA Panel on Genetically Modiﬁed Organisms), 2015b. Statement on the risk assessment of
new sequencing data on GM maize event GA21. EFSA Journal 2015;13(11):4296, 6 pp. https://doi.org/10.
2903/j.efsa.2015.4296
EFSA GMO Panel (EFSA Panel on Genetically Modiﬁed Organisms), 2016. Scientiﬁc Opinion on an application by
Syngenta (EFSA-GMO-DE-2011-99) for the placing on the market of maize Bt11 9 59122 9 MIR604 9 1507 9
GA21 and twenty subcombinations, which have not been authorised previously independently of their origin,
for food and feed uses, import and processing under Regulation (EC) No 1829/2003. EFSA Journal 2016;
14(8):4567, 31 pp. https://doi.org/10.2903/j.efsa.2016.4567
EFSA GMO Panel (EFSA Panel on genetically modiﬁed organisms), Naegeli H, Birch AN, Casacuberta J, De Schrijver
A, Gralak MA, Guerche P, Jones H, Manachini B, Messean A, Nielsen EE, Nogue F, Robaglia C, Rostoks N, Sweet
J, Tebbe C, Visioli F, Wal J-M, Alvarez F, Ardizzone M, Mestdagh S and Ramon M, 2017a. Scientiﬁc opinion on
an application for renewal of authorisation for continued marketing of maize 1507 and derived food and feed
submitted under Articles 11 and 23 of Regulation (EC) No 1829/2003 by Pioneer Overseas Corporation and
Dow AgroSciences LLC. EFSA Journal 2017;15(1):4659, 11 pp. https://doi.org/10.2903/j.efsa.2017.4659
EFSA GMO Panel (EFSA Panel on genetically modiﬁed organisms), Naegeli H, Birch AN, Casacuberta J, De Schrijver
A, Gralak MA, Guerche P, Jones H, Manachini B, Messean A, Nielsen EE, Nogue F, Robaglia C, Rostoks N, Sweet
J, Tebbe C, Visioli F, Wal J-M, Alvarez F, Ardizzone M and Papadopoulou N, 2017b. Scientiﬁc opinion on the
assessment of genetically modiﬁed maize GA21 for renewal of authorisation under Regulation (EC) No 1829/
2003 (application EFSA-GMO-RX-005). EFSA Journal 2017;15(10):5006, 11 pp. https://doi.org/10.2903/j.efsa.
2017.5006
EFSA GMO Panel (EFSA Panel on Genetically Modiﬁed Organisms), Naegeli H, Birch AN, Casacuberta J, De
Schrijver A, Gralak MA, Guerche P, Jones H, Manachini B, Messean A, Nielsen EE, Nogue F, Robaglia C, Rostoks
N, Sweet J, Tebbe C, Visioli F, Wal J-M and Paraskevopoulos K, 2017c. Statement on the risk assessment of
information on the subcombination Bt11 9 MIR162, related to the application of Syngenta (EFSA-GMO-DE-
2009-66) for authorisation of food and feed containing, consisting and produced from genetically modiﬁed
maize Bt11 9 MIR162 9 MIR604 9 GA21. EFSA Journal 2017;15(3):4745, 8 pp. https://doi.org/10.2903/j.efsa.
2017.4745
Assessment of maize Bt11 x MIR162 x 1507 x GA21 and subcombinations
www.efsa.europa.eu/efsajournal 27 EFSA Journal 2018;16(7):5309
EFSA GMO Panel (EFSA Panel on Genetically Modiﬁed Organisms), Naegeli H, Birch AN, Casacuberta J, De
Schrijver A, Gralak MA, Guerche P, Jones H, Manachini B, Messean A, Nielsen EE, Nogue F, Robaglia C, Rostoks
N, Sweet J, Tebbe C, Visioli F, Wal J-M, Neri FM and Paraskevopoulos K, 2017d. Statement on the risk
assessment of information on the subcombination Bt11 9 1507 9 GA21, related to the application of Syngenta
(EFSA-GMO-DE-2011-99) for authorisation of food and feed containing, consisting and produced from
genetically modiﬁed maize Bt11 9 59122 9 MIR604 9 1507 9 GA21. EFSA Journal 2017;15(12):5092, 10 pp.
https://doi.org/10.2903/j.efsa.2017.5092
EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2010. Scientiﬁc Opinion on the
substantiation of health claims related to lutein and maintenance of vision (ID 1603, 1604, 1931) pursuant to
Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2010; 8(2):1492, 19 pp. https://doi.org/10.2903/
j.efsa.2010.1492
EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2012. Scientiﬁc Opinion on the
substantiation of health claims related to lutein and maintenance of normal vision (ID 1603, 1604, further
assessment) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2012;10(6):2716, 17 pp.
https://doi.org/10.2903/j.efsa.2012.2716
EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2015. Scientiﬁc opinion on Dietary
Reference Values for vitamin A. EFSA Journal 2015;13(3):4028, 84 pp. https://doi.org/10.2903/j.efsa.2015.4028
Eisenhauer B, Natoli S, Liew G and Flood VM, 2017. Lutein and zeaxanthin-food sources, bioavailability and dietary
variety in age-related macular degeneration protection. Nutrients, 9, 120.
Estruch JJ, Warren GW, Mullins MA, Nye GJ, Craig JA and Koziel MG, 1996. Vip3A, a novel Bacillus thuringiensis
vegetative insecticidal protein with a wide spectrum of activities against lepidopteran insects. Proceedings of
the National Academy of Sciences of the United States of America, 93, 5389–5394.
Fang J, Xu X, Wang P, Zhao JZ, Shelton AM, Cheng J, Feng MG and Shen Z, 2007. Characterization of chimeric
Bacillus thuringiensis Vip3 toxins. Applied and Environmental Microbiology, 73, 956–961.
Gruber S, Colbach N, Barbottin A and Pekrun C, 2008. Post-harvest gene escape and approaches for minimizing it.
CAB Reviews: Perspectives in Agriculture, Veterinary Science, Nutrition and Natural Resources, 3, 1–17.
Hammond B, Kough J, Herouet-Guicheney C, Jez JM; on behalf of the ILSI International Food Biotechnology
Committee Task Force on the Use of Mammalian Toxicology Studies in the Safety Assessment of GM Foods,
2013. Toxicological evaluation of proteins introduced into food crops. Critical Reviews in Toxicology, 43(Suppl
2), 25–42.
Herrmann KM, 1995. The Shikimate Pathway: early steps in the biosynthesis of aromatic compounds. Plant Cell, 7,
907–919.
Humphries JM and Khachik F, 2003. Distribution of lutein, zeaxanthin, and related geometrical isomers in fruits,
vegetables, wheat, and pasta products. Journal of Agricultural and Food Chemistry, 51, 1322–1327.
Koch MS, Ward JM, Levine SL, Baum JA, Vicini JL and Hammond BG, 2015. The food and environmental safety of
Bt crops. Frontiers in Plant Science, 6, 283. Published online 2015 April 29. https://doi.org/10.3389/fpls.2015.
00283
Lebrun M, Sailland A, Freyssinet G and Degryse E, 2003. Mutated 5-enoylpyruvylshikimate-3-phosphate synthase,
gene coding for said protein and transformed plants containing said gene. US6566587, United States Patent
and Trademark Ofﬁce.
Lecoq E, Holt K, Janssens J, Legris G, Pleysier A, Tinland B and Wandelt C, 2007. General surveillance: roles and
responsibilities the industry view. Journal of Consumer Protection and Food Safety, 2(S1), 25–28.
Markovitz A, Sydiskis RJ and Lieberman MM, 1967. Genetic and biochemical studies on mannose-negative mutants
that are deﬁcient in phosphomannose isomerase in Escherichia coli K-12. Journal of Bacteriology, 94, 1492–1496.
Negrotto D, Jolley M, Beer S, Wenck AR and Hansen G, 2000. The use of phosphomannose-isomerase as a
selectable marker to recover transgenic maize plants (Zea mays L.) via Agrobacterium transformation. Plant
Cell Reports, 19, 798–803.
OECD (Organisation for Economic Co-operation and Development), 2002. Consensus Document on compositional
considerations for new varieties of maize (Zea mays): key food and feed nutrients, anti-nutrients and
secondary plant metabolites. Series on the Safety of Novel Food and Feeds, No 6, 1–42.
OECD (Organisation for Economic Co-operation and Development), 2003. Consensus Document on the biology of
Zea mays subsp. Mays (Maize). Series on Harmonisation of Regulatory Oversight in Biotechnology (ENV/JM/
MONO(2003)11), No 27, 1–49.
Owens BF, Lipka AE, Magallanes-Lundback M, Tiede T, Diepenbrock CH, Kandianis CB, Kim E, Cepela J,
MateosHernandez M, Buell CR, Buckler ES, DellaPenna D, Gore MA and Rocheford TR, 2014. A foundation for
provitamin A biofortiﬁcation of maize: genome-wide association and genomic prediction models of carotenoid
levels. Genetics, 198, 1699–1716.
Palaudelmas M, Pe~nas G, Mele E, Serra J, Salvia J, Pla M, Nadal A and Messeguer J, 2009. Effect of volunteers on
maize gene ﬂow. Transgenic Research, 18, 583–594.
Pascher K, 2016. Spread of volunteer and feral maize plants in Central Europe: recent data from Austria.
Environmental Sciences Europe, 28, 30.
Perry A, Rasmussen H and Johnson EJ, 2009. Xanthophyll (lutein, zeaxanthin) content of fruits, vegetables and
corn and egg products. Journal of Food Composition and Analysis, 22, 9–15.
Assessment of maize Bt11 x MIR162 x 1507 x GA21 and subcombinations
www.efsa.europa.eu/efsajournal 28 EFSA Journal 2018;16(7):5309
Schnepf E, Crickmore N, Van Rie J, Lereclus D, Baum J, Feitelson J, Zeigler DR and Dean DH, 1998. Bacillus
thuringiensis and its pesticidal crystal proteins. Microbiology and Molecular Biology Reviews, 62, 775–806.
Thompson GA, Hiatt WR, Facciotti D, Stalker DM and Comai L, 1987. Expression in Plants of a Bacterial Gene
Coding for Glyphosate Resistance. Weed Science, 35, 19–23.
Trtikova M, Lohn A, Binimelis R, Chapela I, Oehen B, Zemp N, Widmer A and Hilbeck A, 2017. Teosinte in Europe –
Searching for the origin of a novel weed. Scientiﬁc Reports, 71, 1560.
Vazquez RI, Moreno-Fierros L, Neri-Bazan L, de la Riva GA and Lopez-Revilla R, 1999. Bacillus thuringiensis Cry1Ac
protoxin is a potent systemic and mucosal adjuvant. Scandinavian Journal of Immunology, 49, 578–584.
Windels P, Alcalde E, Lecoq E, Legris G, Pleysier A, Tinland B and Wandelt C, 2008. General surveillance for import
and processing: the EuropaBio approach. Journal of Consumer Protection and Food Safety, 3(S2), 14–16.
Wohlleben W, Arnold W, Broer I, Hillemann D, Strauch E and P€uhler A, 1988. Nucleotide sequence of the
phosphinothricin N-acetyltransferase gene from Streptomyces viridochromogenes T€u494 and its expression in
Nicotiana tabacum. Gene, 70, 25–37.
Yuan H, Zhang J, Nageswaran D and Li L, 2015. Carotenoid metabolism and regulation in horticultural crops.
Horticultural Research, 2, 15036.
Abbreviations
ADF acid detergent ﬁbre
ANOVA analysis of variance
bp base pair
Cry Crystal protein
DW dry weight
ERA environmental risk assessment
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Appendix A – Protein expression data
Means, standard deviation and ranges of protein levels (lg/g dry weight) from maize
Bt11 9 MIR162 9 1507 9 GA21, Bt11, MIR162, 1507 and GA21 from ﬁeld trials performed in USA in
2008(a)
Bt11 3 MIR162 3
1507 3 GA21
Bt11 MIR162 1507 GA21
Cry1Ab
Leaf (V10) 15.87(b)  10.53(c)
(3.25–41.50)(d)
3.98  10.53
(1.76–8.93)
Leaf (R1) 16.49  6.17
(2.58–41.93)
5.89  6.17
(2.70–15)
Root (R1) 18.66  3.8
(13.07–29.83)
13.60  3.8
(9.28–17.35)
Pollen (R1) –
< LOQ(f)
–
< LOQ
Grain (R6) 1.07  0.11
(0.91–1.24)
0.91  0.11
(0.65–1.15)
Whole Plant(R1) 3.84  1.22
(1.51–10.28)
2.24  1.22
(1.22–5.14)
PMI
Leaf (V10) 4.79  0.69
(4.10–5.71)
4.25  0.69
(3.55–5.42)
Leaf (R1) 3.81  0.19
(2.41–5.95)
4.29  0.19
(2.80–5.45)
Root (R1) 2.43  0.34
(1.31–3.71)
2.54  0.34
(1.62–3.21)
Pollen (R1) 2.89  0.41
(2.59–3.33)
3.31  0.41
(3–3.71)
Grain (R6) 1.24  0.07
(1.01–1.34)
1.29  0.07
(1.05–1.56)
Whole Plant(R1) 1.97  0.09
(1.60–2.51)
2.19  0.09
(1.8–2.66)
Vip3Aa20
Leaf (V10) 74.05  9.01
(55.3–100.13)
59.38  9.01
(43.61–69.14)
Leaf (R1) 74.17  7.02
(50.50–110.12)
80.44  7.02
(65.54–94.67)
Root (R1) 30.27  2.5
(25.43–34.31)
33.39  2.5
(25.41–39.89)
Pollen (R1) 41.15  6.17
(36.86–44.42)
47.95  6.17
(41.51–59.91)
Grain (R6) 28.48  1.37
(26.52–31.52)
29.02  1.37
(25.92–32.64)
Whole Plant(R1) 23.43  1.61
(20.75–25.62)
30  1.61
(25.40–33.92)
Cry1F
Leaf (V10) 13.32  0.91
(11.06–15.11)
13.83  0.91
(11.83–21.08)
Leaf (R1) 11.67  4.11
(1.79–19.30)
17.17  4.11
(15.13–19.55)
Root (R1) 5.52  0.61
(4.4–7.71)
6.29  0.61
(4.63–8.85)
Pollen (R1) 21.79  1.41
(20.3–23.51)
22.69  1.41
(19.96–26.85)
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Bt11 3 MIR162 3
1507 3 GA21
Bt11 MIR162 1507 GA21
Grain (R6) 3.56  0.19
(3.08–4.49)
3.35  0.19
(2.75–4.28)
Whole Plant(R1) 4.84  0.93
(3.38–7.69)
5.88  0.93
(3.72–7.82)
mEPSPS
Leaf (V10) 31.11  4.01
(19.41–55.38)
31.03  4.01
(22.85–42.09)
Leaf (R1) 12.74  0.77
(8.24–18.35)
21.30  0.77
(16.83–28.26)
Root (R1) 10.74  2.03
(5.7–21.93)
14.08  2.03
(8.36–23.09)
Pollen (R1) 224.06  24.35
(191.48–266.76)
179.84  24.35
(161.96–208.75)
Grain (R6) 5.15  0.86
(3.52–7.09)
4.73  0.86
(2.58–6.56)
Whole Plant(R1) 9.78  1.32
(7.47–12.14)
10.75  1.32
(7.56–12.55)
PAT(e)
Leaf (V10) 4.95  0.54
(4.34–5.91)
0.31  0.09
(0.26–0.56)
4.72  1.08
(3.30–7.18)
Leaf (R1) 4.72  1.92
(1.72–6.85)
0.58  0.07
(0.42–0.68)
6.26  0.74
(4.94–7.20)
Root (R1) 0.72  0.19
(0.33–0.95)
0.73  0.14
(0.51–0.98)
0.35  0.07
(0.23–0.47)
Pollen (R1) –
< LOD(f)
–
< LOD
–
< LOD
Grain (R6) –
< LOD–< LOQ
–
< LOD–< LOQ
–
< LOD
Whole Plant(R1) 1.02  0.38
(0.51–1.67)
0.58  0.12
(0.41–0.75)
1.09  0.33
(0.64–1.7)
(a): Number of samples is n = 10 except for: pollen (n = 5); PMI and Vip3Aa20 in leaves V10 (n = 8 for MIR162); mEPSPS in
leaves V10 (n = 9 for GA21).
(b): Mean.
(c): Standard deviation.
(d): Range.
(e): The standard deviation (SD) values reported for PAT levels in Bt11, 1507 and Bt11 9 MIR162 9 1507 9 GA21 were
determined with descriptive statistics. The SD values for Cry1Ab, PMI, Vip3Aa20, Cry1F and mEPSPS levels were determined
with analysis of variance.
(f): LOD: limit of detection; LOQ: limit of quantiﬁcation; –: not applicable.
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Appendix B – Minority opinion
Application EFSA-GMO-DE-2010-86
(Bt11 3 MIR162 3 1507 3 GA21 maize and three sub combinations independently of
their origin)
Minority Opinion
J.M. Wal, Member of the EFSA GMO Panel
Summary
Application (AP) 86 includes the four-event stack Bt11 x MIR162 x 1507 x GA21 maize and three
subcombinations derived from this stack independently of their origin. Other subcombinations are out
of the scope of the AP. According to the European Union (EU) regulation, the adoption of the four-
event stack Bt11 x MIR162 x 1507 x GA21 maize will, automatically and simultaneously, result in the
adoption of the three subcombinations. This will apply if they are present by natural segregation
during the cultivation of the authorised four-event stack or if they are produced on their own in the
future by targeted conventional breeding techniques, using maize lines different of those used and
assessed in the present AP, and imported in the EU as independent stacks. No speciﬁc data regarding
any of those three subcombinations have been provided by the Applicant, who also did not clearly
justify why it considers that they are not necessary for the risk assessment.
The reason of this minority opinion (MO) is that a risk assessment done without speciﬁc data and
based on assumptions and indirect considerations extrapolated from data obtained with the single
events, the four-event stack and subcombinations previously submitted and assessed cannot be
considered as strong and reliable as a comprehensive one based on a complete set of data,
particularly in the present case when potential unintended adverse effects resulting in an uncontrolled
risk for the health of human consumers in certain segments of the population may be expected.
For the three subcombinations, for which no experimental data were provided, the GMO
Panel assessed the likelihood of interactions among the single events and the newly expressed (NEP)
proteins; it concluded that they are unlikely and that their combinations would not raise safety
concerns. The three maize subcombinations are therefore expected to be as safe as the single events,
the previously assessed subcombinations and the four-event stack maize. The GMO Panel thus
considers that neither additional data nor post-market monitoring is necessary for a comprehensive
assessment of Bt11 x MIR162 x 1507 x GA21 and its three subcombinations.
One may notice that this situation is similar to that of AP 99 i.e. Bt11 x 59122 x MIR604 x 1507 x GA21
maize for which a MO was expressed for the same reasons on 15 July 2016. Therefore, the present MO is
mostly a reiteration of this previous one, emphasising that unfortunately nothing has changed during the
past 2 years to address this issue. However, a reﬂexion has been conducted by the Panel to try to establish
a coherent frame for the assessment of identiﬁed intended/non-intended effects in subcombinations. This
resulted in general proposals that may be applied in this case provided that the Panel clariﬁes the
assumptions made in its assessment and the uncertainty of its approach. Unfortunately, this reﬂexion did
not consider the important issue of the impact of the genetic background of the maize lines used which may
impact on the outcomes of the assessment. Finally, no additional aspects or new considerations have been
taken into account for the safety assessment of AP 86 as compared to that of AP 99 and in particular to
clarify and reduce the uncertainty of the potential speciﬁc risk of those three subcombinations if they are to
be produced in or imported to the EU in the future. Risk management measures that were recommended in
the Scientiﬁc Opinion on AP 99 for following up the subcombinations in the case they are produced have
even not been reiterated in the present one.
Presentation of AP 86
The intended use of the four-event stack is to confer insect resistance and protection against
speciﬁc lepidopteran e.g. Ostrinia nubilalis and Sesamia nonagrioides.
The applicant notiﬁed EFSA that the scope of EFSA-GMO-DE-2010-86 was limited to Bt11 x MIR
162 x 1507 x GA21 maize and its three subcombinations (independently of their origin), that have
never been assessed by EFSA and that may have even not been produced yet. These three
subcombinations are the following: Bt11 x MIR162 x 1507; Bt11 x MIR162 x 1507; MIR162 x 1507
For any of these three subcombinations, no speciﬁc data and no clear explanation regarding why
these missing experimental data were considered not necessary for the safety assessment have been
provided by the Applicant. Regarding the four-event stack, it is also noteworthy that the Applicant did
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not provide data on the levels of expression of the NEPs in forage as required by the Panel and that
the data on the concentrations in the seeds were collected from a ﬁeld trial performed in only one
location; however, the signiﬁcance of these results is not the actual matter of this MO.
The single events: Bt11 (Cry1Ab protein, PAT protein); MIR162 (Vip3Aa20 protein, PMI (Phospho
Mannose Isomerase)); 1507 (Cry1F protein, PAT protein); GA21 (mEPSPS protein) as well as four
subcombinations of two-event stack maize and two of three-event stack maize that are not in the
scope of this application, were previously assessed by EFSA.
Food/Feed safety assessment of AP 86
The comparative analysis of the four-event stack with the conventional counterpart did not identify
differences that would raise concerns regarding the safety or nutritional value for humans and animals.
They were considered not relevant for Food and Feed safety and no further assessment was required.
EFSA has previously performed a toxicological assessment of the NEPs individually in the context of
the single event applications and no safety concerns were identiﬁed. The three insecticidal Bt proteins
(i.e. Cry1Ab, Vip3Aa20 and Cry1F protein), the herbicide tolerant proteins (i.e. PAT and mEPSPS) and
the marker protein PMI were considered unlikely to present a health risk to humans or animals and no
further assessment was required.
As already noted and discussed during the assessment of AP 99, it is noteworthy that Bt proteins
such as Cry1Ab and those structurally and functionally similar have a quite long history of use and are
generally considered safe for mammals because of their speciﬁc mode of action as insecticide (i.e.
high-afﬁnity binding to speciﬁc receptors of insect gut mucosa). However, side effects have been
observed that may affect the immune system following certain conditions of exposure. In particular, a
systemic and mucosal adjuvant activity has been reported in mice after high-dose administrations of
Cry1Ac by the intragastric, intraperitoneal and intranasal routes. Among other effects, an antibody
response against an unrelated protein has been observed showing and adjuvant effect of Cry1Ac on
the immune response (for a review, see 1). Because of these characteristics, Cry proteins such as
Cry1Ac are being proposed as mucosal adjuvant for increasing the efﬁcacy of vaccination.
This issue is in relation with the doses of administration although very little is known regarding the
dose–response relationship and the manifestation of such an adjuvant activity in other Bt proteins than
Cry1Ab and Cry1Ac. It has been shown by different research groups that (i) at the dose at which it is
expressed in MON 810, Cry1Ab did not exert an adjuvant activity (at least for the MON 810 cultivars
that have been tested) and (ii) the adjuvant activity would anyway differ from that of cholera toxin by
its mode of action, which was at this time a major concern expressed by some Member State
Competent Authorities (for a review, see 2).
[For information, it is now thought to be due to a dose-related effect on the innate immunity
system but information on the speciﬁc activity and possible interactions or additivity of the different Bt
proteins are lacking.]
At this time, it was then concluded that, in those single events, the risk of adverse effects because
of an adjuvant activity was unlikely.
In the present four-event stack, the levels of expression of the NEPs are similar to those measured
in the singles. Given the low concentrations of the three Bt proteins, it may be assumed from the
literature that the manifestation of an adjuvant activity by their presence and combination is unlikely
even in the case of a possible additive effect. This conclusion also pertains to the subcombinations
derived from the four-event stack by natural segregation during its cultivation.
There is thus no disagreement with the scientiﬁc opinion of the GMO Panel regarding the four-
event stack and the subcombinations derived from this stack by natural segregation. The disagreement
results from the conclusion on the three ‘sub-combinations independently of their origin’ for which no
data are available. Some of these subcombinations may already exist, but they should mainly be
produced in the future by targeted conventional breeding possibly with maize lines different from
those used in the four-event stacks, the single events and subcombinations previously assessed. The
Panel expects that the concentrations of the newly expressed Bt proteins will be similar to those
actually measured in the present four-event stack and in the other applications. It made no reservation
regarding higher expressions levels that could occur, presently or in the future in different conditions of
breeding, assuming that the variability of the expression levels due to environmental conditions will
remain low and implicitly not taking into account a possible impact of the genetic background on the
variability of the levels of NEPs.
Therefore, it considers, according to the General Strategy for the risk assessment of
subcombinations in segregating stacks (3), that no further data are needed to conclude on the safety
Assessment of maize Bt11 x MIR162 x 1507 x GA21 and subcombinations
www.efsa.europa.eu/efsajournal 33 EFSA Journal 2018;16(7):5309
of the subcombinations. Indeed, unintended effects on the immune system have never been identiﬁed
in any application where Bt proteins were expressed; but at the same time, it should also be noted
that they could not be observed by the toxicological studies (i.e. 28-day repeated-dose tox studies
and/or 90-day feeding trials) currently recommended and performed for the safety assessment of GM
plants at EFSA because they do not include appropriate tests for this purpose.
As a consequence of the conclusion of the scientiﬁc opinion, even in the absence of actual
compositional data, stacks eventually produced in the future would be de facto authorised and could
be imported in the EU without any further assessment or possible post-marketing programme or any
other restrictive risk management measures as recommended in the same situation for AP99.
However, compositional data and reliable information on the actual concentrations of the NEPs are
crucial to achieve a sound safety assessment. Indeed, it has been shown that the genetic background of
the recipient plant has a major effect on Cry1Ac expression in GM cotton (4) and maize (5, 6); it may
cause an additional variability (not taken into account by the GMO Panel so far) in Bt protein
concentrations which might impact on the safety. The risk of increased expression of the newly expressed
Bt proteins and of a possible cumulative effect of their combination on the immune system (e.g. resulting
in an adjuvant activity) cannot be ruled out although it is difﬁcult to evaluate in the absence of actual
experimental data. Indeed, the scope of AP 86 is for import and processing which suggests a limited
exposure for consumers in the EU. Nevertheless, should those subcombinations (or some of them) be
produced and commercialised in the future, the resulting risk for human health, particularly in workers,
might be higher than that of singles or of the fully assessed Bt11 x MIR162 x 1507 x GA21 maize.
Conclusion
It is not acceptable that the same weight and reliability are given to the assessment of a GM crop
for which a complete data set is available and can be comprehensively evaluated and to GM crops for
which no speciﬁc data are provided, particularly when there is a health concern resulting from a
possible over expression of the NEPs.
In the case of AP 86, the safety assessment of the three subcombinations only relies on the data
from the four-event stack, from the single events and from subcombinations previously assessed in
other applications. Despite missing data on comparative analysis, the GMO Panel concludes that it
expects no adverse effect on human health based on an extrapolation. The criteria and procedure
used are not detailed and remain mostly implicit; the level of conﬁdence that should be required for
this extrapolation is not given and there is no critical appraisal of its limitations. No evaluation of the
resulting uncertainty has been performed. These weaknesses may invalidate the conclusion which
anticipates the absence of safety concerns and does not require that additional speciﬁc data shall be
provided to EFSA to guarantee the safety of these three subcombinations should they be produced
and imported to the EU market in the future.
This MO is not only a question of principle since a risk for the human health may result from a
possible over expression of NEPs due to the different factors of variability already mentioned if those
subcombinations were to be produced. Hopefully the risk might be low, but the uncertainty could be
much decreased if sufﬁcient speciﬁc data were provided by the Applicant before all ‘sub-combinations
independently of their origin’ are approved.
Allergic reactions in general and particularly food allergy are dramatically increasing in the EU (and
worldwide) and have become a most important public health issue. The reasons are unclear, but most
specialists involve the changes in environmental conditions, in cultivated plant species and in food
habits. Indeed, environmental conditions are known to play a major role in the occurrence and/or
severity of the allergic reaction in addition to the genetic background of predisposed individuals and
characteristics of the allergen. They include the route and doses of exposure to the protein in question
but also the presence in the food/diet of compounds known to modulate (e.g. increase) the immune
response to other unrelated proteins present in the food. The potential role of these ‘adjuvants’ is
therefore emphasised and especially in the case of immunoglobulin E (IgE)-mediated allergy.
It is thus a pity that a high-double uncertainty due to both a lack of knowledge and a lack of data,
still remains which clariﬁcation would improve the assessment, clarify the role/absence of role of GMOs
in the increasing allergenic risk and ﬁnally allow a solid protection and prevention of at risk consumers.
One solution is at least to reduce the uncertainty on the levels of expression of NEPs by measuring
and collecting actual reliable data for each subcombination through well-designed ﬁeld trials and taking
into account all the factors of variability including the genetic background of varieties used for
producing the subcombinations/stacks.
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The second is to develop and perform methods that would allow identifying unintended effects that
are known and expected. In the present case, a better knowledge of the mechanisms of action of Bt
proteins for a biological activity that coexists with the intended function (e.g. effect of the different Bt
proteins on the immune system vs. insecticide activity) and of the dose–(side) effect relationship would
also allow decreasing the uncertainty of the risk assessment. Such methods adapted for the
identiﬁcation of potential effects on the immune response are available and are already performed.
They are based on the administration of repeated doses of the NEP to well-known appropriate animal
models (review in 1, 7, 8, 9) and/or even administration of the whole GM diet in the context of
adapted 90-day feeding studies (10), then measuring a set of biomarkers of immunity and of the
antibody response in blood samples collected at different time points.
So far, none of these studies has demonstrated signiﬁcant/relevant adverse effects in the conditions
they were performed. That is why, it is most important to continue performing such studies even if
they are not fully validated in order to hopefully discard any increased allergenic risk due to GMOs with
stronger arguments than implicit and highly uncertain assumptions.
Should the present situation remain, this might increase consumers questioning, fear and rejection
of GMOs.
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